

# Guide to HEDIS® Measures MY 2023

Prepared by:  
**Quality Performance Management**  
**HEDIS® Operations**

Version 16\_12/2022

LA1494 02/23



**L.A. Care**  
HEALTH PLAN®

**For All of L.A.**

Welcome to Guide to HEDIS® Measures.....	1
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB).....	2
Adults' Access to Preventative/Ambulatory Health Services (AAP).....	4
Advance Care Planning (ACP).....	6
Follow-Up Care for Children Prescribed ADHD Medication (ADD).....	8
Antidepressant Medication Management (AMM).....	11
Asthma Medication Ratio (AMR).....	14
Breast Cancer Screening (BCS-E).....	17
Blood Pressure Control for Patients with Diabetes (BPD).....	20
Controlling High Blood Pressure (CBP).....	22
Cervical Cancer Screening (CCS).....	25
Chlamydia Screening in Women (CHL).....	28
Childhood Immunization Status (CIS).....	30
Care for Older Adults (COA).....	34
Colorectal Cancer Screening (COL).....	39
Cardiac Rehabilitation (CRE).....	42
Appropriate Testing for Children with Pharyngitis (CWP).....	44
Use of High-Risk Medications in the elderly (DAE).....	50
Deprescribing of Benzodiazepines in Older Adults (DBO).....	52
Potentially Harmful Drug-Disease Interactions in the Older Adults (DDE).....	55
Depression Remission or Response for Adolescents and Adults (DRR-E).....	61
Depression Screening and Follow-up for Adolescents and Adults (DSF-E*).....	63
Emergency Department Visits for Hypoglycemia in Older Adults With Diabetes (EDH).....	66
Eye Exam for Patients with Diabetes (EED).....	68
Follow-Up after Emergency Department Visit for Substance Use (FUA).....	70
Follow-Up After Hospitalization for Mental Illness (FUH).....	72
Follow-Up after Emergency Department Visit for Mental Illness (FUM).....	75
Hemoglobin A1C Control for Patients with Diabetes (HBD).....	77
Initiation and Engagement of Substance Use Disorder Treatment (IET).....	79
Immunizations for Adolescents (IMA).....	82
Kidney Health Evaluation for Patients With Diabetes (KED).....	85
Use of Imaging Studies for Low Back Pain (LBP).....	87
Lead Screening in Children (LSC).....	89
Oral Evaluation, Dental Services (OED).....	90
Osteoporosis Management in Women Who Had a Fracture (OMW).....	93
Osteoporosis Screening in Older Women (OSW).....	97
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH).....	99
Pharmacotherapy Management of COPD Exacerbation (PCE).....	101
Plan All-Cause Readmissions (PCR).....	104
Postpartum Depression Screening (PDS-E).....	105
Prenatal Depression Screening and Follow-Up (PND-E).....	109
Prenatal and Postpartum Care (PPC).....	112
Prenatal Immunization Status (PRS-E).....	117
Statin Therapy for Patients with Cardiovascular Disease (SPC).....	119
Statin Therapy for Patients with Diabetes (SPD).....	123
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR).....	127
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD).....	129
Topical Fluoride for Children (TFC).....	133
Transitions of Care (TRC).....	134
Appropriate Treatment for Children with Upper Respiratory Infection (URI).....	137
Well-Child Visits in the First 30 Months of Life (W30).....	139
Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC).....	141
Child and Adolescent Well-Care Visits (WCV).....	144

# Welcome to Guide to HEDIS® Measures MY 2023



**For All of L.A.**

L.A. Care Health Plan (L.A. Care) is a National Committee for Quality Assurance (NCQA) accredited health plan. HEDIS® is the gold standard for measuring quality health care performance, and is part of the NCQA accreditation process. Guide to HEDIS® Measures is a reference guide designed to help your practice provide the best quality care, in alignment with the HEDIS® standards. This document is merely a tool and provides a general summary on some limited HEDIS® Program requirements. This document should not be used as legal advice or expert advice or comprehensive summary of the HEDIS® Program. Please refer to [ncqa.org](https://www.ncqa.org) for HEDIS® Program measures and guidelines as well as relevant statutes.

The information provided in this document is for 2023 HEDIS® measurement period and is current at the time this document was created. NCQA HEDIS® Program requirements, applicable laws, and L.A. Care's policy change from time to time, and information and documents requested from you may also change to comply with these requirements

L.A. Care is not affiliated with NCQA or its HEDIS® Program and does not receive any financial remuneration from it.

Guide to HEDIS® Measures highlights priority HEDIS® measures that can potentially have significant impact on Auto-assignment and Minimum Performance Level (MPL), NCQA Accreditation, and Cal Medi-Connect (CMC) Quality Performance Withhold. Additionally, if you participate in and qualify for Physician P4P, the information contained in this reference guide may help you maximize the incentives you receive as part of L.A. Care's Physician Pay-for-Performance Program for Medi-Cal and L.A. Care Covered members.

L.A. Care Health Plan collects HEDIS® data throughout the measurement year and reports annually from January to May for the prior year. For example, 2023 claims, encounters, and other HEDIS® data are submitted throughout 2023. In January to May of 2024, data for 2023 continues to be submitted along with Medical Record review for Hybrid measures and final HEDIS® 2023 rates and results are reported.

For HEDIS® related inquiries, please contact [HEDIS\\_Ops@lacare.org](mailto:HEDIS_Ops@lacare.org). *Note: All emails containing member PHI MUST be securely encrypted.*

Pay-for-Performance: Look for measures with Pay-for-Performance that are included in L.A. Care's Pay-for-Performance programs for Measurement Year 2023.

For more details contact [incentive\\_ops@lacare.org](mailto:incentive_ops@lacare.org). *Note: All emails containing member PHI MUST be securely encrypted.*

# Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis/Bronchiolitis (AAB)

Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid

## Q: Which members are included in the sample?

**A:** Members ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that were not dispensed an antibiotic treatment.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data with a date of service from any outpatient, telephonic, e-visit or virtual check-in, an observation or ED visit with an acute bronchitis diagnosis and no new or refill prescription for an antibiotic medication in 2023.

### AAB Antibiotic Medications

Description	Prescription
Aminoglycosides	<ul style="list-style-type: none"> <li>Amikacin</li> <li>Gentamicin</li> <li>Streptomycin</li> <li>Tobramycin</li> </ul>
Aminopenicillins	<ul style="list-style-type: none"> <li>Amoxicillin</li> <li>Ampicillin</li> </ul>
Beta-lactamase inhibitors	<ul style="list-style-type: none"> <li>Amoxicillin-clavulanate</li> <li>Ampicillin-sulbactam</li> <li>Piperacillin-tazobactam</li> </ul>
First-generation cephalosporins	<ul style="list-style-type: none"> <li>Cefadroxil</li> <li>Cefazolin</li> <li>Cephalexin</li> </ul>
Fourth-generation cephalosporins	<ul style="list-style-type: none"> <li>Cefepime</li> </ul>
Lincomycin derivatives	<ul style="list-style-type: none"> <li>Clindamycin</li> <li>Lincomycin</li> </ul>
Macrolides	<ul style="list-style-type: none"> <li>Azithromycin</li> <li>Clarithromycin</li> <li>Erythromycin</li> </ul>
Miscellaneous antibiotics	<ul style="list-style-type: none"> <li>Aztreonam</li> <li>Chloramphenicol</li> <li>Dalfopristin-quinupristin</li> <li>Daptomycin</li> <li>Linezolid</li> <li>Metronidazole</li> <li>Vancomycin</li> </ul>
Natural penicillins	<ul style="list-style-type: none"> <li>Penicillin G benzathine- procaine</li> <li>Penicillin G potassium</li> <li>Penicillin G procaine</li> <li>Penicillin G sodium</li> <li>Penicillin V potassium</li> <li>Penicillin G benzathine</li> </ul>
Penicillinase resistant penicillins	<ul style="list-style-type: none"> <li>Dicloxacillin</li> <li>Nafcillin</li> <li>Oxacillin</li> </ul>
Quinolones	<ul style="list-style-type: none"> <li>Ciprofloxacin</li> <li>Gemifloxacin</li> <li>Levofloxacin</li> <li>Moxifloxacin</li> <li>Ofloxacin</li> </ul>
Rifamycin derivatives	<ul style="list-style-type: none"> <li>Rifampin</li> </ul>
Second-generation cephalosporin	<ul style="list-style-type: none"> <li>Cefaclor</li> <li>Cefotetan</li> <li>Cefoxitin</li> <li>Cefprozil</li> <li>Cefuroxime</li> </ul>
Sulfonamides	<ul style="list-style-type: none"> <li>Sulfadiazine</li> <li>Sulfamethoxazole-trimethoprim</li> </ul>
Tetracyclines	<ul style="list-style-type: none"> <li>Doxycycline</li> <li>Minocycline</li> <li>Tetracycline</li> </ul>
Third-generation cephalosporins	<ul style="list-style-type: none"> <li>Cefdinir</li> <li>Cefixime</li> <li>Cefotaxime</li> <li>Cefpodoxime</li> <li>Ceftazidime</li> <li>Ceftriaxone</li> </ul>
Urinary-anti-infectives	<ul style="list-style-type: none"> <li>Fosfomycin</li> <li>Nitrofurantoin</li> <li>Nitrofurantoin macrocrystals-monohydrate</li> <li>Trimethoprim</li> </ul>

# Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis/Bronchiolitis (AAB)

Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes.
- Timely submission of claim/encounter data

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Acute Bronchitis	J20.0-J20.9
------------------	-------------

### CPT codes

Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99429, 99455, 99456
------------	--

### CPT Telephonic and Telehealth codes

99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

### Exclusion(s)

Comorbid Conditions, Competing Diagnosis, COPD, Cystic Fibrosis, Disorders of Immune System, Emphysema, HIV, HIV Type 2, Hospice Care, Malignant Neoplasms, Other Malignant Neoplasms of Skin, and Pharyngitis.

\*Exclude members who died during 2023.

*Note: Do not include visits that result in inpatient stay.*

# Adult's Access to Preventative/ Ambulatory Health Services (AAP)

## Q: Which members are included in the sample?

**A:** Members 20 years and older who had an ambulatory or preventative care visit.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of medical record is acceptable?

**A:** Evidence from a claim/encounter with a date of service.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes.
- Timely submission of claims and encounter data

# Adult's Access to Preventative/ Ambulatory Health Services (AAP)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

98966-98968, 99212-99215, 99441-99444

### HCPCS codes

G0402, G0438-39, G0463, G2010, G2012, G2061-63, S0620-21, T1015

### Exclusion(s)

Hospice Care

\* Exclude members who died during 2023.

# Advance Care Planning (ACP)

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Members 66-80 years of age with advanced illness, an indication of frailty or who are receiving palliative care, and adults 81 years of age and older who had advance care planning during 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claims/encounter data submission only using the appropriate codes. Including : Advanced Illness, Frailty, and Palliative Care codes

## Q: What type of document is acceptable?

**A:** Evidence of claims/encounter for a discussion or documentation about preferences for resuscitation, life sustaining treatment and end of life care.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Exclusion: Hospice Care



# Advance Care Planning (ACP)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT II codes

Advance Care Planning	1123F, 1124F
-----------------------	--------------

### CPT codes

Assessment of and care planning	99483
---------------------------------	-------

### Exclusion(s)

Members in hospice or using hospice services anytime during 2023, Palliative Care. .

\*Exclude members who died during 2023.

# Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

## Q: Which members are included in the sample?

- A:** Children 6-12 years of age prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported.
- Initiation Phase. The percentage of members 6-12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
  - Continuation and Maintenance (C&M) Phase. The percentage of members 6-12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

# Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

1. Children in the specified age range who were dispensed an ADHD medication:

### *ADHD Medications*

Drug Class	Prescription	Medication Lists
CNS stimulants	<ul style="list-style-type: none"><li>• Dexmethylphenidate</li><li>• Dextroamphetamine</li><li>• Lisdexamfetamine</li><li>• Methylphenidate</li><li>• Methamphetamine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Dexmethylphenidate Medications List</a></li><li>• <a href="#">Dextroamphetamine Medications List</a></li><li>• <a href="#">Lisdexamfetamine Medications List</a></li><li>• <a href="#">Methylphenidate Medications List</a></li><li>• <a href="#">Methamphetamine Medications List</a></li></ul>
Alpha-2 receptor agonists	<ul style="list-style-type: none"><li>• Clonidine</li><li>• Guanfacine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Clonidine Medications List</a></li><li>• <a href="#">Guanfacine Medications List</a></li></ul>
Miscellaneous ADHD medications	<ul style="list-style-type: none"><li>• Atomoxetine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Atomoxetine Medications List</a></li></ul>

2. Member follow-up visit with a practitioner with prescribing authority, within 30 days of ADHD medication dispensing:
  - Of these members, in the following 9 months, who received at least 2 additional follow-up visits with any practitioner

## Q: How to improve score for this HEDIS® measure?

**A:**

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data for any of the following: outpatient visit ,observation visit, Health and Behavior assessment or intervention visit, intensive outpatient encounter or partial hospitalization visit,Community Mental Health Center visit,telephone visit, E- Visit or Virtual Check- In.
- ☑ Schedule 30-day follow-up for all children who are dispensed ADHD medication to assess how medication is working

# Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

## SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

### ICD-10 codes

Attention-Deficit Hyperactivity Disorder: F90.0-F90.2, F90.8-F90.9

### CPT codes

ADD Stand Alone Visits	96150-96154, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99401-99404, 99411, 99412, 99510
ADD Visits Group 1	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
ADD Visits Group 2	99221-99223, 99231-99233, 99238, 99239, 99251-99255
Outpatient	99391-99394

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

ADD Stand Alone Visits	G0155, G0176, G0177, G0409- G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485, T1015
------------------------	---

### Exclusion(s)

Hospice Care, Acute Inpatient Stay, Mental Disorder, Behavioral Disorder, Neurodevelopmental Disorder, Narcolepsy

\*Exclude members who died during 2023.

# Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Adults 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment.

1. *Effective Acute Phase of Treatment.* The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).
2. *Effective Continuation Phase Treatment.* The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

# Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

1. Diagnosis of major depression and date of the earliest dispensing event for an antidepressant medication:

### *ADHD Medications*

Drug Class	Prescription	Medication Lists
CNS stimulants	<ul style="list-style-type: none"><li>• Dexmethylphenidate</li><li>• Dextroamphetamine</li><li>• Lisdexamfetamine</li><li>• Methylphenidate</li><li>• Methamphetamine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Dexmethylphenidate Medications List</a></li><li>• <a href="#">Dextroamphetamine Medications List</a></li><li>• <a href="#">Lisdexamfetamine Medications List</a></li><li>• <a href="#">Methylphenidate Medications List</a></li><li>• <a href="#">Methamphetamine Medications List</a></li></ul>
Alpha-2 receptor agonists	<ul style="list-style-type: none"><li>• Clonidine</li><li>• Guanfacine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Clonidine Medications List</a></li><li>• <a href="#">Guanfacine Medications List</a></li></ul>
Miscellaneous ADHD medications	<ul style="list-style-type: none"><li>• Atomoxetine</li></ul>	<ul style="list-style-type: none"><li>• <a href="#">Atomoxetine Medications List</a></li></ul>

2. Calendar days covered with prescriptions within the specified 180-day (6-month) measurement interval based on pharmacy claims.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

1. Diagnosis of major depression and date of the earliest dispensing event for an antidepressant medication:

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Submission of services rendered during a telephone visit, e-visit, or virtual check-in meet criteria.
- Follow Practice Guidelines for the Treatment of Patients with Major Depressive Disorders
- Treat members with diagnosis of major depression for at least six months
- Utilize the PHQ-9 assessment tool in management of depression
- Educate members that it might take up to 4 weeks for therapeutic effect and of possible medication side effects

# Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Major Depression	F32.0-F32.4, F32.9, F33.0-F33.3, F33.41, F33.9
------------------	--

### CPT codes

AMM Stand Alone Visits	98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99510
AMM Visits	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90867-90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255
ED	99281-99285

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

AMM Stand Alone Visits	G0155, G0176, G0177, G0409-G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485, T1015
------------------------	--

### Exclusion(s)

Hospice Care and No diagnosis of Major Depression  
\*Exclude members who died during 2023.

# Asthma Medication Ratio (AMR)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes.
- Timely submission of claim/encounter data



# Asthma Medication Ratio (AMR)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data with documentation of all asthma medications for members identified as having persistent asthma during 2023.

### Asthma Controller Medication

Description	Prescriptions	Medication Lists	Route
Antibody inhibitors	• Omalizumab	<a href="#">Omalizumab Medications List</a>	Injection
Anti-interleukin-4	• Dupilumab	<a href="#">Dupilumab Medications List</a>	Injection
Anti-interleukin-5	• Benralizumab	<a href="#">Benralizumab Medications List</a>	Injection
Anti-interleukin-5	• Mepolizumab	<a href="#">Mepolizumab Medications List</a>	Injection
Anti-interleukin-5	• Reslizumab	<a href="#">Reslizumab Medications List</a>	Injection
Inhaled steroid combinations	• Budesonide-formoterol	<a href="#">Budesonide Formoterol Medications List</a>	Inhalation
Inhaled steroid combinations	• Fluticasone-salmeterol	<a href="#">Fluticasone Salmeterol Medications List</a>	Inhalation
Inhaled steroid combinations	• Fluticasone-vilanterol	<a href="#">Fluticasone Vilanterol Medications List</a>	Inhalation
Inhaled steroid combinations	• Formoterol-mometasone	<a href="#">Formoterol Mometasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Beclomethasone	<a href="#">Beclomethasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Budesonide	<a href="#">Budesonide Medications List</a>	Inhalation
Inhaled corticosteroids	• Ciclesonide	<a href="#">Ciclesonide Medications List</a>	Inhalation
Inhaled corticosteroids	• Flunisolide	<a href="#">Flunisolide Medications List</a>	Inhalation
Inhaled corticosteroids	• Fluticasone	<a href="#">Fluticasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Mometasone	<a href="#">Mometasone Medications List</a>	Inhalation
Leukotriene modifiers	• Montelukast	<a href="#">Montelukast Medications List</a>	Oral
Leukotriene modifiers	• Zafirlukast	<a href="#">Zafirlukast Medications List</a>	Oral
Leukotriene modifiers	• Zileuton	<a href="#">Zileuton Medications List</a>	Oral
Methylxanthines	• Theophylline	<a href="#">Theophylline Medications List</a>	Oral

### Asthma Reliever Medications

Description	Prescription	Medication Lists	Route
Short-acting, inhaled beta-2 agonists	• Albuterol	• Albuterol Medications List	• Inhalation
Short-acting, inhaled beta-2 agonists	• Levalbuterol	• Levalbuterol Medications List	• Inhalation

# Asthma Medication Ratio (AMR)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

ICD-10 codes - Asthma	
Mild Intermittent Asthma	J45.20-J45.22
Mild Persistent Asthma	J45.30-J45.32
Moderate Persistent Asthma	J45.40-J45.42
Severe Persistent Asthma	J45.50-J45.52
Other and Unspecified Asthma	J45.901-J45.902, J45.909, J45.990, J45.991, J45.998

CPT codes	
ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483

CPT Telephonic and Telehealth codes
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

Modifier codes for telehealth
95, GT, 02

HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015

## Exclusion(s)

Acute Respiratory Failure, Chronic respiratory Conditions Due to Fumes/Vapors, COPD, Cystic Fibrosis, Emphysema, Hospice Care, Obstructive Chronic Bronchitis, Other Emphysema.

\*Exclude members who died in 2023.

# Breast Cancer Screening (BCS-E\*)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Women 50-74 years of age who had one or more mammograms to screen for breast cancer any time on or between 10/1/2021-12/31/2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate value set codes.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Note that mammograms do not need prior authorization and share list of nearby contracted imaging/mammography centers with member
- Educate female members about the importance of early detection, address common barriers/fears, and encourage testing
- Proper coding or documentation of mastectomy either bilateral or unilateral – *to assist in excluding member from the HEDIS® sample. See below for exclusion criteria:*
- Exclusions: Palliative Care and Hospice Care
- Exclusions: for Breast Cancer Screening: (Use designated Value Set Code for each)

Any of the following meet criteria for bilateral mastectomy:

- Bilateral Mastectomy
- Unilateral Mastectomy with bilateral modifier must be from the same procedure.

# Breast Cancer Screening (BCS-E\*)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: How to improve score for this HEDIS® measure?

- Two unilateral mastectomies with service dates 14 days or more apart
- Unilateral mastectomy with right-side modifier with same date of service
- Unilateral mastectomy with left-side modifier with same date of service

*Note: Biopsies, breast ultrasounds and MRIs are not appropriate methods for breast cancer screening.*

# Breast Cancer Screening (BCS-E\*)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

Mammography

77055-77057, 77061-77063, 77065-77067

### HCPCS codes

Mammography

G0202, G0204, G0206

### Exclusion(s)

Absence of Left Breast, Absence of Right Breast, Acute Inpatient, Advanced Illness, Bilateral, Mastectomy, Frailty, History of Bilateral Mastectomy, Hospice Care, Observation, Outpatient, Unilateral Mastectomy, Palliative Care.

# Blood Pressure Control for Patients with Diabetes (BPD)

Pay-for-Performance (P4P)

NCQA Accreditation Medicaid

NCQA Accreditation Medicare (CMC)

Medicare Stars

## Q: Which members are included in the sample?

**A:** Members 18-75 years of age with diabetes (Type 1 and 2) whose blood pressure (BP) was adequately controlled (<140/90) in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

BP cuffs are now a RX benefit for Medi-Cal members. No authorization is needed, just a prescription with a diagnosis code that justifies medical necessity for cardiovascular monitoring for a chronic condition or on a regular basis. necessary.

## Q: What documentation is needed in the medical record?

**A: Blood Pressure (BP) control (< 140/90 mmHG)**

- The most recent BP reading during an outpatient visit, or in a non-acute inpatient/ER setting in 2022. (Note: ALWAYS recheck BP if initial reading is at or > 140/90 mm Hg)
- Member reported BP reading during Telehealth visit.
- BP readings documented as an “average BP” are eligible for use. DO NOT USE RANGES or THRESHOLDS.

**DO NOT INCLUDE BP Reading:**

- Taken during an acute inpatient stay or ED visit.
- Taken by the member using a non-digital device such as with a manual blood pressure cuff and a stethoscope DOES NOT MEET CRITERIA.

## Q: What type of document is acceptable?

**A:** All progress notes from office and Telehealth visits in 2023.

## Q: How to improve score for this HEDIS® measure?

**A:**

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ During Telehealth visits, Blood pressure readings taken and reported by the member meet criteria if taken with a digital device.
- ☑ BP cuffs are now a RX benefit for Medi-Cal members. No authorization is needed, just a prescription with a diagnosis code that justifies medical necessity for cardiovascular monitoring for a chronic condition or on a regular basis. necessary.
- ☑ Exclusion: Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2022 and 2023, I-SNP, LTI, Frailty, Advanced Illness.

# Blood Pressure Control for Patients with Diabetes (BPD)

Pay-for-Performance (P4P)

NCQA Accreditation Medicaid

NCQA Accreditation Medicare (CMC)

Medicare Stars

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Systolic	3074F, 3075F, 3077F
Diastolic	3078F, 3079F, 3080F

### Exclusion(s)

Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2022 and 2023, I-SNP, LTI, Frailty, Advanced Illness

\*Exclude members who died during 2023.

# Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Members 18-85 years of age who had at least two visits on different dates of service with a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg) in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Notation of the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record in 2023. (*Note: ALWAYS recheck BP if initial reading is at or > 140/90 mm Hg*)  
BP reading must occur on or after the date when the second diagnosis of hypertension occurred.  
BP readings taken and reported by member using *any* digital device.  
BP documented as an “average BP” (e.g., “average BP: 139/70”) is eligible to use.

## Q: What type of medical record is acceptable?

**A:** All progress notes in 2023



# Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (DSNP)

Pay-for-Performance (P4P)

Medicare STARS

Medi-Cal Accountability Set (MCAS)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ During Telehealth visits, Blood pressure readings taken and reported by the member meet criteria if taken with a digital device
- ☑ Submit any documentation with ESRD, Pregnancy, Kidney transplant or dialysis - *documentation will assist in excluding members from the HEDIS® sample*
- ☑ BP cuffs are now a RX benefit for Medi-Cal members. No authorization is needed, just a prescription with a diagnosis code that justifies medical necessity for cardiovascular monitoring for a chronic condition or on a regular basis. necessary.
- ☑ Exclusion: Members with diagnosis of pregnancy in 2023. Total or partial Nephrectomy.
- ☑ Exclusion: Palliative Care and Hospice Care
- ☑ Exclusion: For Medicare - members 66 years and older living in long term in institutional settings

# Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Essential Hypertension

I10

Diabetes

Refer to Diabetes Value Set

### CPT codes

Outpatient

99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483

CPT II codes

3074F—Systolic <130

3075F—Systolic 130-139

3078F—Diastolic <80

3079F—Diastolic 80-89

3077F—Systolic 140 or greater

3080F—Diastolic 90 or greater

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Outpatient

G0402, G0438, G0439, G0463, T1015

### Exclusion(s)

Acute Inpatient, Palliative Care, Advanced Illness, ESRD, ESRD Obsolete, Frailty, Inpatient Stay, Kidney Transplant, Transplant, Non-acute Inpatient Stay, Pregnancy, Hospice Care.

\*Exclude members who died during 2023.

# Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** The percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21-64 years of age who had cervical cytology performed within 2021, 2022, or 2023.
- Women 30-64 years of age who had cervical high- risk human papillomavirus (hrHPV) testing performed within 2019, 2020, 2021, 2022 or 2023.
- Women 30-64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) testing within 2019, 2020, 2021, 2022 or 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation must include both of the following criteria:

- a note indicating the date test was performed, *and*
- the result or finding

## Q: What type of medical record is acceptable?

**A:** Acceptable document:

- Cervical cytology report/HPV report
- Chronic Problem List with documentation of Pap Smear with or without HPV, must include date and result
- Progress note or consultation- notation of date and result of Pap Smear/HPV testing.
- Documentation that members with history of hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix meets exclusion (optional) criteria.
- Any of the following documentation meets criteria:
  1. “Complete”, “Total”, or “Radical” (abdominal, vaginal or unspecified)
  2. “vaginal hysterectomy”
  3. “vaginal pap smear” in conjunction with documentation of “hysterectomy”
  4. “hysterectomy” in combination with documentation that the patient no longer needs pap testing/ cervical cancer screening.

# Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Ensure proper documentation in medical record
- Request results of screenings be sent to you if done at OB/GYN visit
- Exclusion: Palliative Care, Hospice Care, Hysterectomy with no residual cervix, cervical agenesis, acquired absence of cervix, or vaginal hysterectomy

# Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

Cervical Cytology	88141-88143, 88147, 88148, 88150, 88152-88154, 88164-88167, 88174, 88175
HPV Tests	87620-87622, 87624, 87625

### HCPCS codes

Cervical Cytology	G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
HPV Tests	G0476

### Exclusion(s)

Absence of Cervix, Palliative Care, Hospice Care, Encounter for Palliative Care

\*Exclude members who died during 2023

# Chlamydia Screening in Women (CHL)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia in **2023**.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation in the medical record is acceptable?

**A:** *None*. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data

- One chlamydia test in **2023**

## Q: How to improve score for this HEDIS® measure?

**A:**

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ For all those on birth control pills, make chlamydia screening a standard lab
- ☑ Remember that chlamydia screening can be performed through a simple urine test-offer this as an option for your members
- ☑ Proper coding or documentation will assist in excluding members from the HEDIS® sample
- ☑ Exclude members based on a pregnancy test alone **and** who meet either of the following:
  - A pregnancy test in 2023 **and** a prescription for isotretinoin (Retinoid) on the date of pregnancy test or the 6 days after the pregnancy test
  - A pregnancy test in 2023 **and** an x-ray on the date of the pregnancy test or the 6 days after the pregnancy test

# Chlamydia Screening in Women (CHL)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to Pregnancy Value Set  
Refer to Pregnancy Tests Value Set  
Refer to Sexual Activity Value Set

### CPT codes

Chlamydia Tests	87110, 87270, 87320, 87490-87492, 87810
Pregnancy Tests	81025, 84702, 84703
Sexual Activity	Refer to Sexual Activity Value Set

### HCPCS codes

Sexual Activity	G0101, G0123, G0124, G0141, G0143-G0145, G0147, G0148, H1000, H1001, H1003-H1005, P3000, P3001, Q0091, S0199, S4981, S8055
-----------------	--

### Exclusion(s)

Hospice Care, A pregnancy test in 2023 and a Rx for isotretinoin on the day of pregnancy test or 6 days after test  
OR A pregnancy test in 2023 and an x-ray on the date of the pregnancy test or 6 days after test.

\*Exclude members who died during 2023.

# Childhood Immunization Status (CIS)

State Medicaid Auto – Assignment (Combo 10)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines **by their second birthday**. LAIV(Influenza) vaccination must occur on the child's second birthday.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation must include any of the following:

*Specific for: MMR, HepB, VZV, and HepA*

- Evidence of the antigen or combination vaccine (include specific dates)
- Documented history of the illness

*Specific for: DTaP, HiB, IPV, PCV, rotavirus, and influenza*

- Evidence of the antigen or combination vaccine (include specific dates)

### **OR**

- Notation indicating contraindication for a specific vaccine:  
(Use designated Value Set Codes for each)

Any Particular Vaccine	<ul style="list-style-type: none"><li>• Anaphylactic reaction to the vaccine or its components</li></ul>
DTaP	<ul style="list-style-type: none"><li>• Encephalopathy <i>with</i> a vaccine adverse-effect code</li></ul>
MMR, VZV, and Influenza	<ul style="list-style-type: none"><li>• Immunodeficiency</li><li>• HIV</li><li>• Anaphylactic reaction to neomycin</li><li>• Lymphoreticular cancer, Multiple Myeloma, or Leukemia</li></ul>
Rotavirus	<ul style="list-style-type: none"><li>• Severe combined immunodeficiency</li><li>• History of intussusception</li></ul>



# Childhood Immunization Status (CIS)

State Medicaid Auto – Assignment (Combo 10)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: What documentation is needed in the medical record?

### OR

- ☑ Notation indicating contraindication for a specific vaccine:  
(Use designated Value Set for each)

IPV	Anaphylactic reaction to streptomycin, polymyxin B or neomycin
Hepatitis B	Anaphylactic reaction to common baker's yeast

## Q: What type of medical record is acceptable?

**A:** One or more of the following:

- ☑ Certificate of immunization including specific dates and types of vaccines
- ☑ Hospital record with notation of HepB
- ☑ Immunization Record and Health History Form
- ☑ Health Maintenance Form
- ☑ Lab report for seropositive test
- ☑ Print out of LINK/CAIR registry
- ☑ Progress/office notes with notations of vaccines given
- ☑ Medical History Form

## Q: How to improve score for this HEDIS® measure?

- A:**
- ☑ Upload immunizations on to California Immunizations Registry (<http://cairweb.org>)
  - ☑ Use the Childhood and Adolescent Wellness Flyers for Providers as a guideline of recommended health services for certain age groups ([http://www.lacare.org/sites/default/files/LA1401\\_0815.pdf](http://www.lacare.org/sites/default/files/LA1401_0815.pdf))
  - ☑ Educate parents about the importance of timely vaccinations and share the immunization schedule
  - ☑ Use of complete and accurate Value Set Codes
  - ☑ Timely submission of claim/encounter data
  - ☑ Ensure proper documentation of dates and types of immunizations, test results, history of illness, or contraindication for a specific vaccine

*Note:* Exclude children who have immunocompromising conditions or contraindication for a specific vaccine

# Childhood Immunization Status (CIS)

State Medicaid Auto – Assignment (Combo 10)  
 State Medicaid MPL (must achieve 50th percentile or greater)  
 Pay-for-Performance (P4P)  
 NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

ICD-10 PC code	
Newborn Hepatitis B	3E0234Z

  

CPT codes	
Dtap-IPV-Hib-HepB	90697
DTap Vaccine	90698, 90700, 90721, 90723
Haemophilus Influenzae Type B (HiB) Vaccine	90644-90648, 90698, 90721, 90748
Hepatitis A Vaccine	90633
Hepatitis B Vaccine	90723, 90740, 90744, 90747, 90748
Inactivated Polio Vaccine (IPV)	90698, 90713, 90723
Influenza Vaccine	90655, 90657, 90661, 90662, 90673, 90685-90688
Measles, Mumps and Rubella Vaccine	90707, 90710
Pneumococcal Conjugate Vaccine	90670
Rotavirus Vaccine (2 dose)	90681
Rotavirus Vaccine (3 dose)	90680
Varicella Zoster Vaccine	90710, 90716

# Childhood Immunization Status (CIS)

State Medicaid Auto – Assignment (Combo 10)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## HCPCS codes

Influenza	G0008
Pneumococcal	G0009
Hepatitis B Vaccine	G0010

## Exclusion(s)

Anaphylaxis due to vaccine is numerator compliant for DTaP, IPV, MMR, HiB, HepB, VZV, PCV, HepA, Rotavirus, and FLU. Encephalitis due to vaccine is numerator compliant for DTaP only, Disorders of Immune System, HIV, Intussusception, Malignant Neoplasm of Lymphatic Tissue, Severe Combined Immunodeficiency, Vaccine Causing Adverse Effect, Hospice Care.

\*Exclude members who died during 2023.

# Care for Older Adults (COA)

## Q: Which members are included in the sample?

**A:** Adults 66 years and older who had *each* of the following in **2023**:

- Medication review
- Functional status assessment
- Pain assessment

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:**

- Evidence of Medication Review** – must include medication list in the medical record, and evidence of a medication review and the date when it was performed *or* notation that the member is not taking any medication and the date when it was noted
- Evidence of Functional Status Assessment** – documentation must include evidence of functional status assessment *and* the date when it was performed
- Evidence of Pain Assessment** – documentation must include evidence of a pain assessment (may include positive or negative findings for pain) and the date when it was performed

# Care for Older Adults (COA)

## Q: What type of medical record is acceptable?

**A:**

### **Medication Review:**

- Current medication list in 2023
- Notation of medication review in 2023
- Date and notation that the member is not taking any medication in 2023

*Note: Medication Review does not require member to be present.*

### **Functional Status Assessment:**

- Progress notes, IHSS forms, HRA forms, AWE form
- Notation that Activities of Daily Living (ADL) were assessed or that at least 5 of the following were assessed: bathing, dressing, eating, transferring [e.g., getting in and out of chairs], using toilet, walking
- Notation that Instrumental Activities of Daily Living (IADL) were assessed or at least 4 of the following were assessed: shopping for groceries, driving or using public transportation, using the telephone, meal preparation, housework, home repair, laundry, taking medications, handling finances
- Result of assessment using a standardized functional status assessment tool

# Care for Older Adults (COA)

## Q: What type of medical record is acceptable?

### A: Pain Assessment:

- ☑ Progress notes – notation of a pain assessment (which may include positive or negative findings for pain)
- ☑ Result of assessment using a standardized pain assessment tool
- ☑ Numeric rating scales (verbal or written)
- ☑ Pain Thermometer
- ☑ Pictorial Pain Scales
- ☑ Visual Analogue Scale
- ☑ Brief Pain Inventory
- ☑ Chronic Pain Grade
- ☑ PROMIS Pain Intensity Scale
- ☑ Pain Assessment in Advanced Dementia (PAINAD) Scale

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Submission of services rendered during a telephone visit, e-visit, or virtual check-in meet criteria.
- ☑ Ensure presence of all components in the medical record documentation
- ☑ Timely submission of complete and accurate AWE Forms
- ☑ Exclude services provided in an acute inpatient setting

# Care for Older Adults (COA)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 Codes

N/A

### CPT Codes

Medication Review	90863, 99483, 99605, 99606
TCM 14 day	99495
TCM 7 day	99496

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### CPT II Codes

Pain Assessment	1125F, 1126F
Medication List	1159F
Medication Review	1160F
Functional Status Assessment	1170F

# Care for Older Adults (COA)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### HCPCS codes

Medication List

G8427

### Exclusion(s)

Acute Inpatient, Acute Inpatient POS, Hospice Care

\*Exclude members who died during 2023.



# Colorectal Cancer Screening (COL)

NCQA Accreditation – Medicare  
NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 45-75 years of age who had appropriate screenings for colorectal cancer.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation in the medical record must include a note indicating the **date** the colorectal cancer screening was performed. Appropriate screenings are defined by **any** of the following:

- Fecal Occult Blood Test in **2023**; guaiac (gFOBT) or immunochemical (FIT)
- Flexible sigmoidoscopy performed in **2019, 2020, 2021, 2022, or 2023**
- Colonoscopy in **2023 or within 9 years prior to 2023**
- CT colonography performed in **2019, 2020, 2021, 2022, or 2023**
- Stool DNA (Cologuard) with FIT test report in **2021, 2022, or 2023**

## Q: What type of medical record is acceptable?

**A:** One or more of the following:

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Health Maintenance Form   | <input checked="" type="checkbox"/> Pathology report without indicating the type of screening but has evidence that the scope advanced beyond the splenic flexure or sigmoid colon |
| <input checked="" type="checkbox"/> Progress notes/Office visits notes  | <input checked="" type="checkbox"/> Medical History Forms  |
| <input checked="" type="checkbox"/> Problem List  | <input checked="" type="checkbox"/> GI Consults/ Reports/ Flowcharts   |
| <input checked="" type="checkbox"/> Laboratory/Pathology Reports  | <input checked="" type="checkbox"/> Complete Physical Examination Form   |
| <input checked="" type="checkbox"/> Pathology report that indicates the type of screening (e.g., colonoscopy or flexible sigmoidoscopy) |  |

*Note: Do not count digital rectal exams (DRE), FOBT tests performed in an office setting or performed on a sample collected via DRE.*

# Colorectal Cancer Screening (COL)

NCQA Accreditation – Medicare

NCQA Accreditation – Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Prior to each visit for members 45 years and older, review chart to determine if COL screening has been completed, if not, discuss options with member, as colonoscopy every 10 years and stool testing done yearly are shown to have similar effectiveness in identifying colon cancer
- ☑ Request a supply of stool screening test kits from your contracted lab(s) to have on hand to share with members when at office visits
- ☑ If a member had a colonoscopy, the provider's office should ask the member for a copy of the report or the rendering provider's contact information to request the report and save a copy in the member's medical record
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation
- ☑ Exclusions: Members with diagnosis of colorectal cancer or total colectomy.

# Colorectal Cancer Screening (COL)

NCQA Accreditation – Medicare

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

FOBT	82270, 82274
Flexible Sigmoidoscopy	45330-45335, 45337-45342, 45345-45347, 45349, 45350
Colonoscopy	44388-44394, 44397, 44401-44408, 45355, 45378-45393, 45398
CT Colonography	74261-74263
Stool DNA (sDNA) with FIT test	81528

### HCPCS codes

FOBT	G0328
Flexible Sigmoidoscopy	G0104
Colonoscopy	G0105, G0121
Colorectal Cancer (PET scan)	G0213-G0215, G0231
Stool DNA (sDNA) with FIT test	G0464

### Exclusion(s)

Advanced Illness, Palliative Care, Colorectal Cancer, Frailty, Hospice Care, Total Colectomy

\*Exclude member who died during 2023.

# Cardiac Rehabilitation (CRE)

## Q: Which members are included in the sample?

- A:** Members 18 years and older, who attended cardiac rehabilitation following a qualifying cardiac event, including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement. Four rates are reported:
- *Initiation.* The percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event.
  - *Engagement 1.* The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event.
  - *Engagement 2.* The percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.
  - *Achievement.* The percentage of member who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data

# Cardiac Rehabilitation (CRE)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Codes

99201-99205, 99211-99215, 99241-99244

### CPT Telephonic and Telehealth Codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier Codes for Telehealth

95, GT, 02

### HCPCS Codes

G0402, G0438, G0439, G0463, T1015

### Exclusion(s)

MI, CABG, Heart or heart/lung transplant, Heart valve repair or transplant, PCI, Hospice setting/services, Palliative care, I-SNP, LTI, Frailty and Advance Illness.

\*Exclude member who died during 2023.

# Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 3 years and older, who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode (7/1/2022 - 6/30/2023) during any outpatient, telephone, observation or ED visit, and e-visit or virtual check-in.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence of claim/encounter data:

- Date of service for an outpatient or ED visit with a diagnosis of pharyngitis
- Throat culture lab report
- Date and result of strep test with a diagnosis of pharyngitis
- Antibiotic prescription for the episode

# Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Antibiotic Medications:

Description	Prescription		
Aminopenicillins	• Amoxicillin	• Ampicillin	
Beta lactamase inhibitors	• Amoxicillin-clavulanate		
First generation cephalosporins	• Cefadroxil • Cefazolin	• Cephalexin	
Folate antagonist	• Trimethoprim		
Lincomycin derivatives	• Clindamycin		
Macrolides	• Azithromycin • Clarithromycin • Erythromycin		
Natural penicillins	• Penicillin G Benzathine • Penicillin G potassium • Penicillin G sodium	• Penicillin V potassium	
Quinolones	• Ciprofloxacin • Levofloxacin	• Moxifloxacin • Ofloxacin	
Second generation cephalosporins	• Cefaclor • Cefprozil	• Cefuroxime	
Sulfonamides	• Sulfamethoxazole-trimethopim		
Tetracyclines	• Doxycycline • Minocycline	• Tetracycline	
Third generation cephalosporins	• Cefdinir • Cefixime	• Cefpodoxime	• Ceftriaxone

## Q: How to improve score for this HEDIS® measure?

A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Ensure presence of all components in the medical record documentation

# Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Pharyngitis	J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91
-------------	---

### CPT codes

Group A Strep Tests	87070, 87071, 87081, 87430, 87650-87652, 87880
---------------------	--

Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
------------	--

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205
---

### CPT Modifier codes for telehealth

95, GT, 02
------------

### HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

### Exclusion(s)

Hospice Care, Inpatient Stay

\*Exclude members who died during 2023.



# Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** The percentage of Medicare members 67 years of age and older who had at least two dispensing events for the same high-risk medication to avoid from the same drug class, except for appropriate diagnoses.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of documentation is acceptable?

**A:** Evidence from a claim/encounter data:

- Two dispensing event(s) for a high-risk medication in 2023.

# Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

## High-Risk Medications

Description	Prescription	Medication Lists	Description	Prescription	Medication Lists
Anticholinergics, first-generation antihistamines	<ul style="list-style-type: none"> <li>Brompheniramine</li> <li>Carbinoxamine</li> <li>Chlorpheniramine</li> <li>Clemastine</li> <li>Cyproheptadine</li> <li>Dexbrompheniramine</li> <li>Dexchlorpheniramine</li> <li>Diphenhydramine (oral)</li> <li>Dimenhydrinate</li> <li>Doxylamine</li> <li>Hydroxyzine</li> <li>Mecizine</li> <li>Promethazine</li> <li>Pyrilamine</li> <li>Triprolidine</li> </ul>	<ul style="list-style-type: none"> <li>Brompheniramine Medications List</li> <li>Carbinoxamine Medications List</li> <li>Chlorpheniramine Medications List</li> <li>Clemastine Medications List</li> <li>Cyproheptadine Medications List</li> <li>Dexbrompheniramine Medications List</li> <li>Dexchlorpheniramine Medications List</li> <li>Diphenhydramine Medications List</li> <li>Dimenhydrinate Medications List</li> <li>Doxylamine Medications List</li> <li>Hydroxyzine Medications List</li> <li>Mecizine Medications List</li> <li>Promethazine Medications List</li> <li>Pyrilamine Medications List</li> <li>Triprolidine Medications List</li> </ul>	Central nervous system, vasodilators	<ul style="list-style-type: none"> <li>Ergoloid mesylates</li> <li>Isoxsuprine</li> </ul>	<ul style="list-style-type: none"> <li>Ergoloid Mesylates Medications List</li> <li>Isoxsuprine Medications List</li> </ul>
			Central nervous system, other	<ul style="list-style-type: none"> <li>Meprobamate</li> </ul>	<ul style="list-style-type: none"> <li>Meprobamate Medications List</li> </ul>
			Endocrine system, estrogens with or without progestins; include only oral and topical patch products	<ul style="list-style-type: none"> <li>Conjugated estrogen</li> <li>Esterified estrogen</li> <li>Estradiol</li> <li>Estropipate</li> </ul>	<ul style="list-style-type: none"> <li>Conjugated Estrogens Medications List</li> <li>Esterified Estrogens Medications List</li> <li>Estradiol Medications List</li> <li>Estropipate Medications List</li> </ul>
			Endocrine system, sulfonylureas, long-duration	<ul style="list-style-type: none"> <li>Chlorpropamide</li> <li>Glimepiride</li> <li>Glyburide</li> </ul>	<ul style="list-style-type: none"> <li>Chlorpropamide Medications List</li> <li>Glimepiride Medications List</li> <li>Glyburide Medications List</li> </ul>
Anticholinergics, anti-Parkinson agents	<ul style="list-style-type: none"> <li>Benztpopine (oral)</li> <li>Trihexyphenidyl</li> </ul>	<ul style="list-style-type: none"> <li>Benztpopine Medications List</li> <li>Trihexyphenidyl Medications List</li> </ul>	Endocrine system, other	<ul style="list-style-type: none"> <li>Desiccated thyroid</li> <li>Megestrol</li> </ul>	<ul style="list-style-type: none"> <li>Desiccated Thyroid Medications List</li> <li>Megestrol Medications List</li> </ul>
Antispasmodics	<ul style="list-style-type: none"> <li>Atropine (exclude ophthalmic)</li> <li>Belladonna alkaloids</li> <li>Chlordiazepoxide-clidinium</li> <li>Dicyclomine</li> <li>Hyoscyamine</li> <li>Methscopolamine</li> <li>Propantheline</li> <li>Scopolamine</li> </ul>	<ul style="list-style-type: none"> <li>Atropine Medications List</li> <li>Belladonna Medications List</li> <li>Chlordiazepoxide Clidinium Medications List</li> <li>Dicyclomine Medications List</li> <li>Hyoscyamine Medications List</li> <li>Methscopolamine Medications List</li> <li>Propantheline Medications List</li> <li>Scopolamine Medications List</li> </ul>	Nonbenzodiazepine hypnotics	<ul style="list-style-type: none"> <li>Eszopiclone</li> <li>Zaleplon</li> <li>Zolpidem</li> </ul>	<ul style="list-style-type: none"> <li>Nonbenzodiazepine Hypnotics Medications List</li> </ul>
Antithrombotic	<ul style="list-style-type: none"> <li>Dipyridamole, (oral, excluding extended release)</li> </ul>	<ul style="list-style-type: none"> <li>Dipyridamole Medications List</li> </ul>	Pain medications, skeletal muscle relaxants	<ul style="list-style-type: none"> <li>Carisoprodol</li> <li>Chlorzoxazone</li> <li>Cyclobenzaprine</li> <li>Metaxalone</li> <li>Methocarbamol</li> <li>Orphenadrine</li> </ul>	<ul style="list-style-type: none"> <li>Carisoprodol Medications List</li> <li>Chlorzoxazone Medications List</li> <li>Cyclobenzaprine Medications List</li> <li>Metaxalone Medications List</li> <li>Methocarbamol Medications List</li> <li>Orphenadrine Medications List</li> </ul>
Cardiovascular, alpha agonists, central	<ul style="list-style-type: none"> <li>Guanfacine</li> <li>Methyldopa</li> </ul>	<ul style="list-style-type: none"> <li>Guanfacine Medications List</li> <li>Methyldopa Medications List</li> </ul>	Pain medications, other	<ul style="list-style-type: none"> <li>Indomethacin</li> <li>Ketorolac, includes parenteral</li> <li>Meperidine</li> </ul>	<ul style="list-style-type: none"> <li>Indomethacin Medications List</li> <li>Ketorolac Medications List</li> <li>Meperidine Combinations Medications List</li> </ul>
Cardiovascular, other	<ul style="list-style-type: none"> <li>Disopyramide</li> <li>Nifedipine (excluding extended release)</li> </ul>	<ul style="list-style-type: none"> <li>Disopyramide Medications List</li> <li>Nifedipine Medications List</li> </ul>			
Central nervous system, antidepressants	<ul style="list-style-type: none"> <li>Amitriptyline</li> <li>Amoxapine</li> <li>Clomipramine</li> <li>Desipramine</li> <li>Imipramine</li> <li>Nortriptyline</li> <li>Paroxetine</li> <li>Protriptyline</li> <li>Trimipramine</li> </ul>	<ul style="list-style-type: none"> <li>Amitriptyline Medications List</li> <li>Amoxapine Medications List</li> <li>Clomipramine Medications List</li> <li>Desipramine Medications List</li> <li>Imipramine Medications List</li> <li>Nortriptyline Medications List</li> <li>Paroxetine Medications List</li> <li>Protriptyline Medications List</li> <li>Trimipramine Medications List</li> </ul>			
Central nervous system, barbiturates	<ul style="list-style-type: none"> <li>Amobarbital</li> <li>Butabarbital</li> <li>Butalbital</li> <li>Pentobarbital</li> <li>Phenobarbital</li> <li>Secobarbital</li> </ul>	<ul style="list-style-type: none"> <li>Amobarbital Medications List</li> <li>Butabarbital Medications List</li> <li>Butalbital Medications List</li> <li>Pentobarbital Medications List</li> <li>Phenobarbital Medications List</li> <li>Secobarbital Medications List</li> </ul>			

# Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

## High-Risk Medications

### High-Risk Medications Based on Prescription and Diagnosis Data

Drug Class	Prescription	Medication Lists
Antipsychotics, first (conventional) and second (atypical) generation	<ul style="list-style-type: none"> <li>Aripiprazole</li> <li>Aripiprazole lauroxil</li> <li>Asenapine</li> <li>Brexipiprazole</li> <li>Cariprazine</li> <li>Chlorpromazine</li> <li>Clozapine</li> <li>Fluphenazine</li> <li>Haloperidol</li> <li>Iloperidone</li> <li>Loxapine</li> <li>Lurasidone</li> <li>Molindone</li> <li>Olanzapine</li> <li>Paliperidone</li> <li>Perphenazine</li> <li>Pimavanserin</li> <li>Pimozide</li> <li>Quetiapine</li> <li>Risperidone</li> <li>Thioridazine</li> <li>Thiothixene</li> <li>Trifluoperazine</li> <li>Ziprasidone</li> </ul>	<ul style="list-style-type: none"> <li>DAE Antipsychotic Medications List</li> </ul>
Benzodiazepines, long, short and intermediate acting	<ul style="list-style-type: none"> <li>Alprazolam</li> <li>Chlordiazepoxide</li> <li>Clonazepam</li> <li>Clorazepate</li> <li>Diazepam</li> <li>Estazolam</li> <li>Flurazepam</li> <li>Lorazepam</li> <li>Midazolam</li> <li>Oxazepam</li> <li>Quazepam</li> <li>Temazepam</li> <li>Triazolam</li> </ul>	<ul style="list-style-type: none"> <li>Benzodiazepine Medications List</li> </ul>

### High-Risk Medications with Days Supply Criteria

Description	Prescription	Average Daily Dose Criteria	Medication Lists
Anti-Infectives, other	<ul style="list-style-type: none"> <li>Nitrofurantoin</li> <li>Nitrofurantoin macrocrystals-monohydrate</li> </ul>	>90 days	<ul style="list-style-type: none"> <li>High Risk Anti Infectives Medication List</li> </ul>

### High-Risk Medications with Daily Average Dose Criteria

Description	Prescription	Average Daily Dose Criteria	Medication Lists
Alpha agonists, central	<ul style="list-style-type: none"> <li>Reserpine</li> </ul>	>0.1 mg/day	<ul style="list-style-type: none"> <li>Reserpine 0.1 mg Medications List</li> <li>Reserpine 0.25 mg Medications List</li> </ul>
Cardiovascular, other	<ul style="list-style-type: none"> <li>Digoxin</li> </ul>	>0.125 mg/day	<ul style="list-style-type: none"> <li>Digoxin .05 mg per mL Medications List</li> <li>Digoxin .0625 mg Medications List</li> <li>Digoxin .1 mg per mL Medications List</li> <li>Digoxin .125 mg Medications List</li> <li>Digoxin .1875 mg Medications List</li> <li>Digoxin .25 mg Medications List</li> <li>Digoxin .25 mg per mL Medications List</li> </ul>
Tertiary TCAs (as single agent or as part of combination products)	<ul style="list-style-type: none"> <li>Doxepin</li> </ul>	>6 mg/day	<ul style="list-style-type: none"> <li>Doxepin 3 mg Medications List</li> <li>Doxepin 6 mg Medications List</li> <li>Doxepin 10 mg Medications List</li> <li>Doxepin 10 mg per mL Medications List</li> <li>Doxepin 25 mg Medications List</li> <li>Doxepin 50 mg Medications List</li> <li>Doxepin 75 mg Medications List</li> <li>Doxepin 100 mg Medications List</li> <li>Doxepin 150 mg Medications List</li> </ul>

# Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data

# Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT codes

#### Outpatient services:

Office/other outpatient services:	99201-99205, 99211-99215
Consultations	99241-99245
Preventive medicine services	99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

### Exclusion(s)

Hospice Care, Palliative Care, Encounter for Palliative Care

\*Exclude members who died during 2023.

# Deprescribing of Benzodiazepines in Older Adults (DBO)

## Q: Which members are included in the sample?

**A:** Members 67 years of age and older who were dispensed benzodiazepines and achieved a 20% decrease or greater in benzodiazepine dose (diazepam milligram equivalent [DMR] dose in 2023).

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence of claim/encounter data:

**Step 1-** Identify members with two or more benzodiazepine dispensing events on different dates of services (refer to the Oral Benzodiazepine Medications table below for medication list for identifying benzodiazepine dispensing events) during 2023.

**Step 2-** Of the members identified in Step 1, identify those with qualifying Index treatment episode (ITE).

**Step 3-** Of the members identified in Step 2, identify those with PDC > or = 50% during the treatment period.

# Deprescribing of Benzodiazepines in Older Adults (DBO)

## Oral Benzodiazepine Medications

Type of Benzodiazepine	Medication Lists	Strength	DME Conversion Factor
<b>Alprazolam (oral)</b>	Alprazolam 0.25 MG Medications List	0.25 mg	0.1
	Alprazolam 0.5 MG Medications List	0.5 mg	
	Alprazolam 1 MG Medications List	1 mg	
	Alprazolam 1 MG PML Medications List	1 mg	
	Alprazolam 2 MG Medications List	2 mg	
	Alprazolam 3 MG Medications List	3 mg	
<b>Chlordiazepoxide (oral)</b>	Chlordiazepoxide 5 MG Medications List	5 mg	2.5
	Chlordiazepoxide 10 MG Medications List	10 mg	
	Chlordiazepoxide 25 MG Medications List	25 mg	
	Chlordiazepoxide 10 MG Medications List	25 mg	
	Chlordiazepoxide 25 MG Medications List	25 mg	
<b>Clonazepam (oral)</b>	Clonazepam 0.125 MG Medications List	0.125 mg	0.1
	Clonazepam 0.25 MG Medications List	0.25 mg	
	Clonazepam 0.5 MG Medications List	0.5 mg	
	Clonazepam 1 MG Medications List	1 mg	
	Clonazepam 2 MG Medications List	2 mg	
<b>Clorazepate (oral)</b>	Clorazepate 3.75 MG Medications List	3.75 mg	1.5
	Clorazepate 7.5 MG Medications List	7.5 mg	
	Clorazepate 15 MG Medications List	15 mg	
<b>Diazepam (oral)</b>	Diazepam 1 MG PML Medications List	1 mg	1
	Diazepam 2 MG Medications List	2mg	
	Diazepam 5 MG Medications List	5mg	
	Diazepam 5 MG PML Medications List	5mg	
	Diazepam 10 MG Medications List	10 mg	
<b>Estazolam (oral)</b>	Estazolam 1 MG Medications List	1 mg	0.3
	Estazolam 2 MG Medications List	2 mg	
<b>Flurazepam (oral)</b>	Flurazepam 15 MG Medications List	15 mg	3
	Flurazepam 30 MG Medications List	30 mg	
<b>Lorazepam (oral)</b>	Lorazepam 1 MG Medications List	1 mg	0.2
	Lorazepam 2 MG PML Medications List	2 mg	
<b>Midazolam (oral)</b>	Midazolam 2 MG PML Medications List	2 mg	1.5
<b>Oxazepam (oral)</b>	Oxazepam 10 MG Medications List	10 mg	3
	Oxazepam 30 MG Medications List	30 mg	
<b>Quazepam (oral)</b>	Quazepam 15 MG Medications List	15 mg	2
<b>Temazepam (oral)</b>	Temazepam 7.5 MG Medications List	7.5 mg	2
	Temazepam 15 MG Medications List	15 mg	
	Temazepam 22.5 MG Medications List	22.5 mg	
	Temazepam 30 MG Medications List	30 mg	
<b>Triazolam (oral)</b>	Triazolam 0.125 MG Medications List	0.125 mg	0.025
	Triazolam 0.25 MG Medications List	0.25 mg	

# Deprescribing of Benzodiazepines in Older Adults (DBO)

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data.

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### Exclusion(s)

Palliative Care, Hospice encounter



# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Medicare members 65 years and older who have evidence of an underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis between January 1, 2022 - December 1, 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## Q: What type of documentation is acceptable?

**A:** Evidence from claim/encounter data for:

- 1 Rate 1: Drug-Disease Interactions- History of Falls and Antiepileptics, Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics or Antidepressants (SSRIs, Tricyclic Antidepressants and SNRIs)

### Potentially Harmful Drugs—History of Falls Medications

Description	Prescription
Antiepileptics	<ul style="list-style-type: none"> <li>• Carbamazepine</li> <li>• Clobazam</li> <li>• Divalproex sodium</li> <li>• Ethosuximide</li> <li>• Ethotoin</li> <li>• Ezogabine</li> <li>• Felbamate</li> <li>• Fosphenytoin</li> <li>• Gabapentin</li> <li>• Lacosamide</li> <li>• Lamotrigine</li> <li>• Levetiracetam</li> <li>• Methsuximide</li> <li>• Oxcarbazepine</li> <li>• Phenobarbital</li> <li>• Phenytoin</li> <li>• Pregabalin</li> <li>• Primidone</li> <li>• Rufinamide</li> <li>• Tiagabine HCL</li> <li>• Topiramate</li> <li>• Valproic acid</li> <li>• Vigabatrin</li> <li>• Zonisamide</li> </ul>
SNRIs	<ul style="list-style-type: none"> <li>• Desvenlafaxine</li> <li>• Duloxetine</li> <li>• Levomilnacipran</li> <li>• Venlafaxine</li> </ul>
SSRIs	<ul style="list-style-type: none"> <li>• Citalopram</li> <li>• Escitalopram</li> <li>• Fluoxetine</li> <li>• Fluvoxamine</li> <li>• Paroxetine</li> <li>• Sertraline</li> </ul>

### Potentially Harmful Drugs—History of Falls and Dementia Medications

Description	Prescription
Antipsychotics	<ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Asenapine</li> <li>• Brexpiprazole</li> <li>• Cariprazine</li> <li>• Chlorpromazine</li> <li>• Clozapine</li> <li>• Fluphenazine</li> <li>• Haloperidol</li> <li>• Iloperidone</li> <li>• Loxapine</li> <li>• Lurasidone</li> <li>• Molindone</li> <li>• Olanzapine</li> <li>• Paliperidone</li> <li>• Perphenazine</li> <li>• Pimozide</li> <li>• Quetiapine</li> <li>• Risperidone</li> <li>• Thioridazine</li> <li>• Thiothixene</li> <li>• Trifluoperazine</li> <li>• Ziprasidone</li> </ul>
Benzodiazepines	<ul style="list-style-type: none"> <li>• Alprazolam</li> <li>• Chlordiazepoxide</li> <li>• Clonazepam</li> <li>• Clorazepate</li> <li>• Diazepam</li> <li>• Estazolam</li> <li>• Flurazepam</li> <li>• Lorazepam</li> <li>• Midazolam</li> <li>• Oxazepam</li> <li>• Quazepam</li> <li>• Temazepam</li> <li>• Triazolam</li> </ul>
Nonbenzodiazepine hypnotics	<ul style="list-style-type: none"> <li>• Eszopiclone</li> <li>• Zaleplon</li> <li>• Zolpidem</li> </ul>
Tricyclic antidepressants	<ul style="list-style-type: none"> <li>• Amitriptyline</li> <li>• Amoxapine</li> <li>• Clomipramine</li> <li>• Desipramine</li> <li>• Doxepin (&gt;6 mg)</li> <li>• Imipramine</li> <li>• Nortriptyline</li> <li>• Protriptyline</li> <li>• Trimipramine</li> </ul>

# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## Q: What type of documentation is acceptable?

- 2 Drug-Disease Interactions- Dementia and Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics, Tricyclic Antidepressants or Anticholinergic Agents

### Dementia Medications

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> <li>Donepezil</li> <li>Galantamine</li> <li>Rivastigmine</li> </ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> <li>Memantine</li> </ul>
Dementia combinations	<ul style="list-style-type: none"> <li>Donepezil-memantine</li> </ul>

### Potentially Harmful Drugs—Dementia Medications

Description	Prescription
Anticholinergic agents, antiemetics	<ul style="list-style-type: none"> <li>Prochlorperazine</li> <li>Promethazine</li> </ul>
Anticholinergic agents, antihistamines	<ul style="list-style-type: none"> <li>Brompheniramine</li> <li>Carbinoxamine</li> <li>Chlorpheniramine</li> <li>Clemastine</li> <li>Cyproheptadine</li> <li>Dexbrompheniramine</li> <li>Dexchlorpheniramine</li> <li>Dimenhydrinate</li> <li>Diphenhydramine</li> <li>Doxylamine</li> <li>Pyrilamine</li> <li>Tripolidine</li> <li>Hydroxyzine</li> <li>Meclizine</li> </ul>
Anticholinergic agents, antispasmodics	<ul style="list-style-type: none"> <li>Atropine</li> <li>Belladonna alkaloids</li> <li>Clidinium- chlordiazepoxide</li> <li>Dicyclomine</li> <li>Homatropine</li> <li>Hyoscyamine</li> <li>Methscopolamine</li> <li>Propantheline</li> <li>Scopolamine</li> </ul>
Anticholinergic agents, antimuscarinics (oral)	<ul style="list-style-type: none"> <li>Darifenacin</li> <li>Fesoterodine</li> <li>Flavoxate</li> <li>Oxybutynin</li> <li>Solifenacin</li> <li>Tolterodine</li> <li>Tropium</li> </ul>
Anticholinergic agents, anti- Parkinson agents	<ul style="list-style-type: none"> <li>Benzotropine</li> <li>Trihexyphenidyl</li> </ul>
Anticholinergic agents, skeletal muscle relaxants	<ul style="list-style-type: none"> <li>Cyclobenzaprine</li> <li>Orphenadrine</li> </ul>
Anticholinergic agents, SSRIs	<ul style="list-style-type: none"> <li>Paroxetine</li> </ul>
Anticholinergic agents, antiarrhythmic	<ul style="list-style-type: none"> <li>Disopyramide</li> </ul>

# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## 3. Rate 3: Drug- Disease Interactions- Chronic Kidney Disease and Cox-2 Selective NSAIDs or Nonaspirin NSAIDs

### Cox-2 Selective NSAIDs and Nonaspirin NSAIDs Medications

Description	Prescription
Cox-2 Selective NSAIDs	<ul style="list-style-type: none"> <li>Celecoxib</li> </ul>
Nonaspirin NSAIDs	<ul style="list-style-type: none"> <li>Diclofenac</li> <li>Etodolac</li> <li>Fenoprofen</li> <li>Flurbiprofen</li> <li>Ibuprofen</li> <li>Indomethacin</li> <li>Ketoprofen</li> <li>Ketorolac</li> <li>Meclofenamate</li> <li>Mefenamic acid</li> <li>Meloxicam</li> <li>Nabumetone</li> <li>Naproxen</li> <li>Naproxen sodium</li> <li>Oxaprozin</li> <li>Piroxicam</li> <li>Sulindac</li> <li>Tolmetin</li> </ul>

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Exclusions: Palliative Care, Hospice Care

# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

CPT codes	
Hip Fractures	27230, 27232, 27235, 27236, 27238, 27240, 27244-27246, 27248, 27254, 27267-27269, 27767-27769
ESRD	90935, 90937, 90945, 90947, 90997, 90999, 99512, 36800, 36810, 36815, 36819, 36820, 36821, 36831, 36833,

CPT Telephonic and Telehealth codes
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth
95, GT, 02

Outpatient	
E&M, office/other outpatient services	99201-99205, 99211-99215
E&M, hospital observation services	99217-99220
E&M, consultations	99241-99245
E&M, preventive medicine services	99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429
	Palliative Care code

ICD10 CM codes	
Dementia	G30.0, G30.1, G30.8, G30.9, G31.83, 290.0, 290.10 - 290.13, 290.20, 290.21, 290.3, 290.40 – 290.43, 290.8, 290.9, 291.2, 292.82, 294.0, 294.10, 294.11, 294.20
ESRD	Z91.15, Z99.2
Fall/Hip Fracture	Refer to Value Set Directory

# Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

HCPCS Code	
ESRD	G0257, S9339
Outpatient	G0402, G0438, G0439, G0463, T1015

## Exclusion(s)

Palliative Care, Bipolar Disorder, Hospice Care, Other Bipolar Disorder Psychosis, Schizoaffective Disorder, Schizophrenia, or Seizure Disorder on or between January 1, 2022 and December 1, 2023.

# Depression Remission or Response for Adolescents and Adults (DRR-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: Which members are included in the sample?

- A:** Members 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 4-8 months of the elevated score.
- Follow-up PHQ-9. Members who have follow-up PHQ-9 score documented within 4-8 months after the initial elevated PHQ-9 score.
  - *Depression Remission.* Members who achieved remission within 4-8 months after the initial elevated PHQ-9 score.
  - *Depression Response.* Members who achieved remission within 4-8 months after the initial elevated PHQ-9 score.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

- A:** Evidence from claim/encounter data including pharmacy data.

## Q: What type of document is acceptable?

- Use of complete and accurate Value Set Codes.
- Timely submission of claim/encounter data.

# Depression Remission or Response for Adolescents and Adults (DRR-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### LOINC Codes:

PHQ	44261-6, 89204-2
-----	------------------

### Exclusion(s)

Members in hospice or using hospice services any time during 2023. Members with Bipolar disorder, Personality disorder, Psychotic disorder, Pervasive development disorder or/and who died any time during 2023.



# Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)\*

\* Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

## Q: Which members are included in the sample?

- A:** Members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.
- Depression Screening- Members who were screened for clinical depression using a standardized instrument.
  - Follow-Up on Positive Screening- Members who received follow-up care within 30 days of positive depression screen finding.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

# Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)\*

\* Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

## Q: What type of documentation is acceptable?

**A:** Evidence from a claim/encounter data:

- Documentation of standardized age appropriate tool for screening clinical depression.
- Documentation of a follow-up care on or 30 days after the date of the first positive screen (31 days total) from any one of the following.
  - a follow-up behavioral health encounter with or without a telehealth modifier including assessment, therapy, collaborative care, medication management, acute care and health encounters
  - a follow up outpatient visit with a diagnosis of depression or other behavioral health condition, with or without telehealth modifier
  - a telephone visit with diagnosis of depression or other behavioral health condition
  - a follow-up with a case manager with documented assessment of depression symptoms
  - dispensed an antidepressant medication

Depression Screening Instrument	A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:	
	Instruments for Adolescents (12–17 years)	Positive Finding
	Patient Health Questionnaire (PHQ-9) <sup>®</sup>	Total Score ≥10
	Patient Health Questionnaire Modified for Teens (PHQ-9M) <sup>®</sup>	Total Score ≥10
	Patient Health Questionnaire-2 (PHQ-2) <sup>®2</sup>	Total Score ≥3
	Beck Depression Inventory-Fast Screen (BDI-FS) <sup>®1,2</sup>	Total Score ≥8
	Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
	Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥10
	PROMIS Depression	Total Score (T Score) ≥60
	Instruments for Adults (18+ years)	Positive Finding
	Patient Health Questionnaire (PHQ-9) <sup>®</sup>	Total Score ≥10
	Patient Health Questionnaire-2 (PHQ-2) <sup>®2</sup>	Total Score ≥3
	Beck Depression Inventory-Fast Screen (BDI-FS) <sup>®1,2</sup>	Total Score ≥8
	Beck Depression Inventory (BDI-II)	Total Score ≥20
	Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
	Duke Anxiety-Depression Scale (DADS) <sup>®1</sup>	Total Score ≥30
	Geriatric Depression Scale Short Form (GDS) <sup>2</sup>	Total Score ≥5
	Geriatric Depression Scale Long Form (GDS)	Total Score ≥10
	Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥10
	My Mood Monitor (M-3) <sup>®</sup>	Total Score ≥5
	PROMIS Depression	Total Score (T Score) ≥60
	Clinically Useful Depression Outcome Scale (CUDOS)	Total Score ≥31

<sup>1</sup>Proprietary; may be cost or licensing requirement associated with use.  
<sup>2</sup>Brief screening instrument. All other instruments are full-length.

## Q: How to improve score for this HEDIS<sup>®</sup> measure?

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data

# Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)\*

\*Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

## SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

### ICD 10 Codes:

Depression or Other Behavioral Health Condition:	F01.51, F20.0-F20.5, F20.81, F20.89, F20.9
--	--

### CPT Codes:

Behavioral Health Encounter:	90791, 90792, 90832, 90833, 90834, 90836, 90837-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887
------------------------------	--

Depression Case Management Encounter:	99366
---------------------------------------	-------

Follow-Up Visit:	98960-98962, 99078, 99201-99205, 99211 – 99215, 99217-99220, 99241 – 99245, 99341 – 99345, 99347 -99350, 99381 – 99387, 99391 – 99397, 99401 – 99404, 99411, 99412,
------------------	---

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Depression Case Management Encounter:	T1016, T1017, T2022, T2023, G0463, T1015
---------------------------------------	--

### Exclusion(s)

Bipolar Disorder, Hospice Care

# Emergency Department Visits for Hypoglycemia in Older Adults with Diabetes (EDH)

## Q: Which members are included in the sample?

- A:** Members 67 years of age and older with diabetes (types 1 and 2), the risk-adjusted ratio of observed to expected (O/E) emergency department (ED) visits for hypoglycemia during 2023. Two rates are reported.
- For all members 67 years of age and older with diabetes (types 1 and 2), the risk-adjusted ratio of O/E ED visits for hypoglycemia during the measurement year, stratified by dual eligibility.
  - For a subset of members 67 years of age and older with diabetes (types 1 and 2) who had at least one dispensing event of insulin with each 6-month treatment period from July 1 of the year prior to the measurement year through December 31, 2023, the risk-adjusted ratio of O/E ED visits for hypoglycemia, stratified by dual eligibility.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

- A:** Evidence from claim/encounter data including pharmacy data.

## Q: How to improve score for this HEDIS® measure?

- A:**
- \*Use of complete and accurate Value Set Codes.
  - \*Timely submission of claim/encounter data.

# Emergency Department Visits for Hypoglycemia in Older Adults with Diabetes (EDH)

## CPT Codes

Outpatient	98966-98968, 99441-99443, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411-99412
------------	---

## HCPS Codes

G0402, G0438, G0439, G0463, T1015

## Exclusion(s)

Palliative Care, Hospice encounter and members who do not have a diagnosis of diabetes and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid- induced diabetes.

# Eye Exam for Patients with Diabetes (EED)

Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid  
NCQA Accreditation Medicare (CMC)  
Medicare Stars

## Q: Which members are included in the sample?

**A:** Members 18-75 years of age with diabetes (types 1 and 2) who had a retinal eye exam.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:**
- A retinal or dilated eye exam by an eye care professional in 2023, OR
  - A negative retinal or dilated eye exam by an eye care professional in 2022.
  - Request a copy of retinal eye exam, if not received, from members eye specialist .

## Q: What type of document is acceptable?

- A:**
- Retinal eye exam in 2022 or/and 2023 from eye specialist
  - Evidence/notation of bilateral eye enucleation any time prior to December 31, 2023.
  - Eye exam result documentation with “unknown” does not meet criteria.

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data
  - Ensure presence of all components in the medical record documentation
  - Exclusion: Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2022 and 2023, I-SNP, LTI, Frailty, Advanced Illness.

# Eye Exam for Patients with Diabetes (EED)

Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid  
NCQA Accreditation Medicare (CMC)  
Medicare Stars

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD 10 Codes:

Measure Year (Current Year)	2022F, 2023F
Year Prior	3072F

### Exclusion(s)

Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2022 and 2023, I-SNP, LTI, Frailty, Advanced Illness.

\*Exclude members who died during 2023.

# Follow-Up After Emergency Department Visit for Substance Use (FUA)

## Q: Which members are included in the sample?

**A:** Members age 13 years and older who visited an emergency department (ED) with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was a follow-up. Two rates are reported:

1. Members with ED visits who received follow-up within 30 days of the ED visit (31 total days).
2. Members with ED visits who received follow-up within 7 days of the ED visit (8 total days).

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data including pharmacy data.

### ***Alcohol Use Disorder Treatment Medications***

<b>Description</b>	<b>Prescription</b>
Aldehyde dehydrogenase inhibitor	<ul style="list-style-type: none"><li>• Disulfiram (oral)</li></ul>
Antagonist	<ul style="list-style-type: none"><li>• Naltrexone (oral and injectable)</li></ul>
Other	<ul style="list-style-type: none"><li>• Acamprosate (oral; delayed-release tablet)</li></ul>



# Follow-Up After Emergency Department Visit for Substance Use (FUA)

## Opioid Use Disorder Treatment Medications

Description	Prescription	Medication Lists
Antagonist	• Naltrexone (oral)	• Naltrexone Oral Medications List
Antagonist	• Naltrexone (injectable)	• Naltrexone Injection Medications List
Partial agonist	• Buprenorphine (sublingual tablet)	• Buprenorphine Oral Medications List
Partial agonist	• Buprenorphine (injection)	• Buprenorphine Injection Medications List
Partial agonist	• Buprenorphine (implant)	• Buprenorphine Implant Medications List
Partial agonist	• Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)	• Buprenorphine Naloxone Medications List

### Q: How to improve score for this HEDIS® measure?

#### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data

## SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

### CPT Codes

Outpatient 90832-90834, 90836-90839, 90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99233, 99238-99239, 99251-99255

### CPT Telephonic and Telehealth codes

98966-98968, 99441-99443

### CPT Modifier codes for telehealth

95, GT, 02

### Exclusion(s)

Members in hospice or using hospice services any time during 2023. Members who died any time during 2023.

# Follow-Up After Hospitalization for Mental Illness (FUH)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnosis and who had a follow-up visit with a mental health provider. Two rates are reported:

1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
2. The percentage of discharges for which the member received follow-up within 7 days after discharge

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of documentation is acceptable?

**A:** Evidence from a claim/encounter data:

- Documentation of a follow-up visit in 2023 with a mental health provider within 7-30 days of discharge from hospitalization for treatment of mental illness
- Documentaion of a follow-up:
  - Visits in behavioral health settings.
  - Telephone Visits
- Include all discharges on or between January 1, 2023 and December 1, 2023.  
\*Follow-up visits that occur on the date of discharge do not count.

# Follow-Up After Hospitalization for Mental Illness (FUH)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Document hospice care readmission/direct transfer to acute setting for exclusion from the eligible population
- Mental Health Provider: A practitioner who provides mental health services and meets any of the following criteria:
  - An MD or (DO) who is certified or who successfully completed an accredited program in psychiatry or child psychiatry.
  - A licensed psychologist in his/her state of practice
  - A licensed or certified social worker with master's degree and is listed on the National Association of Social Worker's Clinical Register
  - A registered nurse (RN) certified as a psychiatric nurse or mental health clinical nurse specialist and has a master's degree in psychiatric/mental health
  - An individual with a master's or a doctoral degree in marital and family therapy and at least two years of supervised clinical experience who is practicing as a marital and family therapist
  - An individual with a master's or doctoral degree in counseling and at least two years of supervised clinical experience who is practicing as a professional counselor and licensed on the National Board for Certified Counselors (NBCC)

# Follow-Up After Hospitalization for Mental Illness (FUH)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 Codes

Refer to Mental Health Diagnosis Value Set and Mental Illness Value Set

### CPT Codes

FUH Stand Alone Visits:	98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384-99397, 99401-99404, 99408, 99411, 99412, 99483, 99510
FUH Visits Group 1:	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
FUH Visits Group 2:	99221-99223, 99231-99233, 99238, 99239, 99251-99255
TCM 14 Day:	99495
TCM 7 Day:	99496

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS Codes

FUH Stand Alone Visits:	G0155, G0176, G0177, G0409, G0410, G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, S0201, S9480, S9484, S9485, T1015
-------------------------	---

### Exclusion(s)

Hospice Care, Nonacute Inpatient Stay

\*Exclude members who died during 2023.

# Follow-Up After Emergency Department Visit for Mental Illness (FUM)

## Q: Which members are included in the sample?

**A:** Members age 6 years and older who visited an emergency department (ED) with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:

1. Members with ED visits who received follow-up within 30 days of the ED visit (31 total days).
2. Members with ED visits who received follow-up within 7 days of the ED visit (8 total days).

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of documentation is acceptable?

**A:** Evidence from claim/encounter data.

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data

# Follow-Up After Emergency Department Visit for Mental Illness (FUM)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

CPT Codes	
Outpatient	99217-99219, 9920
FUH Visits Group 1:	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
FUH Visits Group 2:	99221-99223, 99231-99233, 99238, 99239, 99251-99255
TCM 14 Day:	99495
TCM 7 Day:	99496

CPT Telephonic and Telehealth codes
98966-98968, 99441-99443.

CPT Modifier codes for telehealth
95, GT, 02

HCPCS Codes	
Outpatient	G2010, G2012, G2061-G2063

Exclusion(s)
Members in hospice or using hospice services any time during 2023. Members who died any time during 2023.

# Hemoglobin A1C Control for Patients with Diabetes (HBD)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid  
NCQA Accreditation Medicare (CMC)  
Medicare Stars

## Q: Which members are included in the sample?

**A:** Members 18-75 years of age with diabetes (Types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during 2023: \*HbA1c control < 8% \* HbA1c poor control > 9%

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:**

- Date of the most recent HbA1c test and the result

## Q: What type of documentation is acceptable?

**A:**

- All progress notes with notation of HbA1c testing with results in 2023.
- Health Maintenance Log
- Lab Reports in 2023

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Ensure presence of all components in the medical record documentation
- Schedule regular follow-up with patients to monitor changes and adjust therapies as needed
- Exclusion: Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2022 and 2023, I-SNP, LTI, Frailty, Advanced Illness and members who died any time during 2023.

# Hemoglobin A1C Control for Patients with Diabetes (HBD)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation Medicaid  
NCQA Accreditation Medicare (CMC)  
Medicare Stars

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

CPT II codes	
7.0%: Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM)2,4	3044F
9.0%: Most recent hemoglobin A1c level greater than 9.0% (DM)2,4	3046F
Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than or equal to 8.0%	3051F
Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0%	3052F

Exclusion(s)
Polycystic Ovarian Syndrome (PCOS), Gestational diabetes or Steroid induced diabetes, Hospice setting/services, Palliative care, No Diagnosis on DM in any setting in 2021 and 2022, I-SNP, LTI, Frailty, Advanced Illness.



# Initiation and Engagement of Substance Use Disorder Treatment (IET)

NCQA Accreditation – Medicaid  
NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

- A:** The percentage of new substance use disorder (SUD) episodes that result in treatment initiation and engagement in 2023 (13 yrs and older) who received the following:
- Initiation of SUD Treatment.* The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visit or medication treatment within 14 days.
  - Engagement of SUD Treatment.* The percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation.

## Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

- A:** Evidence from a claim/encounter data
- Inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalizations, telehealth visit, or medication treatment within 14 days.
  - Claims/encounter for new SUD episodes that have evidence of treatment engagement within 34 days of initiation.

Note: SUD Episode Date - date of service for encounter during the Intake period with a diagnosis of SUD.  
(Intake Period) - November 15, 2022 to November 14, 2023.

# Initiation and Engagement of Substance Use Disorder Treatment (IET)

NCQA Accreditation – Medicaid  
NCQA Accreditation – Medicare (CMC)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Consider screening all members at office and/or telehealth visits using a substance abuse screening tool
- ☑ Once a member is identified with SUD or dependence diagnosis, initiate brief intervention or refer for treatment within 14 days. Then complete at least two brief interventions within 34 days of diagnosis
- ☑ When referring members out to substance abuse providers, ensure an appointment is made within 14 days of diagnosis
- ☑ Exclude members from both Initiation of SUD Treatment and Engagement of SUD Treatment if the initiation of treatment event is an inpatient stay with a discharge date of November 14, 2023. Members in hospice or using hospice services any time during 2023. Members who died any time during 2023.

# Initiation and Engagement of Substance Use Disorder Treatment (IET)

NCQA Accreditation – Medicaid  
NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to Substance use Disorder (SUD) Value Set, Detoxification Value Set

### CPT codes

IET Stand Alone Visits	98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99408, 99409, 99411, 99412, 99483, 99492-99494, 99510
IET Visits Group 1	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
IET Visits Group 2	99221-99223, 99231-99233, 99238, 99239, 99251-99255

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

IET Stand Alone Visits	G0155, G0176, G0177, G0396, G0397, G0409-G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2001, H2010-H2020, H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012, T1015
Detoxification	H0008-H0014

### Exclusion(s)

SUD Abuse and Dependence, SUD Medication Treatment, Hospice Care

# Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 2)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Adolescents who had one dose of meningococcal conjugate vaccine (MCV), one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) and 2 or 3 doses of the human papillomavirus (HPV) vaccines **by their 13<sup>th</sup> birthday.**

- Combo 1 - (Meningococcal, Tdap)
- Combo 2 - (Meningococcal, Tdap, HPV)

*Note: The minimum interval for the two-dose HPV vaccination schedule is 150 days (5 months), with a 4-day grace period (146 days).*

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Must include any of the following:

- A note indicating the name of specific antigen and the date of the immunization
- A certificate of immunization that includes specific dates and types of immunizations administered
- Anaphylactic reaction to the vaccine or its components any time on or before the member's 13<sup>th</sup> birthday
- Encephalopathy with a vaccine adverse-effect anytime on or before the member's 13<sup>th</sup> birthday. (Tdap)

*Meningococcal vaccine* – given between member's 11<sup>th</sup> and 13<sup>th</sup> birthday

*Tdap vaccine* – given between member's 10<sup>th</sup> and 13<sup>th</sup> birthday

*HPV vaccine* – 2-doses (given 146 days apart) or 3 doses given between member's 9<sup>th</sup> and 13<sup>th</sup> birthday

## Q: What type of medical record is acceptable?

**A:** One or more of the following:

- Certificate of immunization including specific dates and types of vaccines
- Immunization Record and health History Form
- Health Maintenance Form/Report
- Print out of CAIR registry
- Progress note/Office visit – with notations of vaccines given
- Notation of anaphylactic reaction to serum or vaccination

# Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 2)

NCQA Accreditation – Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Upload immunizations on to California Immunizations Registry (<http://cairweb.org>)
- ☑ Use the Childhood and Adolescent Wellness Flyers for Providers as a guideline of recommended health services for certain age groups ([http://www.lacare.org/sites/default/files/LA1401\\_0815.pdf](http://www.lacare.org/sites/default/files/LA1401_0815.pdf))
- ☑ Use every office visit (including sick visits) to provide immunizations and well-care visits
- ☑ Educate parents about the importance of timely vaccinations and share the immunization schedule
- ☑ Use EHR alerts to notify parents about needed immunizations
- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation of dates and types of immunizations, or contraindication for a specific vaccine
- ☑ Exclusion: Members in hospice or using hospice services any time during 2023.
- ☑ Members who died any time during 2023.

# Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 2)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

Meningococcal Vaccine	90734
Meningococcal Polysaccharide Vaccine (MPSV4)	90733
Tdap Vaccine	90715
HPV Vaccine	90649-90651

### HCPCS codes

N/A

### Exclusion(s)

Anaphylactic Reaction Due To Serum, Anaphylactic Reaction Due To Vaccination, Encephalopathy Due To Vaccination, Hospice Care, Vaccine Causing Adverse Effect

# Kidney Health Evaluation for Patients With Diabetes (KED)

## Q: Which members are included in the sample?

**A:** Members 18–85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from a claim/encounter of members who received **both** of the following during 2023 on the same or different dates of service:

- At least one eGFR.
- At least one uACR identified by **both** a quantitative urine albumin test **and** a urine creatinine test **with** service dates four or less days apart. For example, if the service date for the quantitative urine albumin test was December 1, 2023, then the urine creatinine test must have a service date on or between November 27, 2023 and December 5, 2023

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes.
- Timely submission of claims and encounter data
- Use of accurate Exclusion Codes
- Perform kidney health evaluation (eGFR) and (uACR) for members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during 2023.

## Exclusion(s)

- Members with evidence of ESRD or dialysis any time during the member's history on or prior to December 31, 2023.
- Members receiving palliative care in 2023
- Members Enrolled in an Institutional SNP (I-SNP) or living long-term in an institution any time in 2023.
- Members with frailty diagnosis during 2023.
- Members in hospice or using hospice services anytime in 2023.
- Members who did not have a diagnosis of diabetes and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes during 2022 or 2023.
- Members who did not have a diagnosis of diabetes **and** who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes during 2022 or 2023.
- Members who died any time during 2023.

# Kidney Health Evaluation for Patients With Diabetes (KED)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

99201-99205, 99211-99215, 99241-99244

### CPT Telephonic and Telehealth Codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier Codes for Telehealth

95, GT, 02

### HCPCS codes

G0402, G0438, G0439, G0463, T1015

### Exclusion(s)

Chronic kidney disease stage 5, End stage renal disease, Dependence on renal dialysis, Hospice Care, Palliative Care.



# Use of Imaging Studies for Low Back Pain (LBP)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 18-75 years of age with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data

- Imaging study with uncomplicated diagnosis of low back pain on the IESD or in the 28 days following the IESD. **Index Episode Start Date (IESD):** The earliest date of service for an outpatient or ED encounter during the Intake Period (January 1, 2023 – December 3, 2023) with a principal diagnosis of low back pain.

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data
  - Proper coding or documentation of any of the following diagnoses for which imaging is clinically appropriate – *to assist in excluding members from the HEDIS® sample. See below for exclusion criteria.*

**Exclusions:** (*Use designated Value Set for each*)

Any of the following meet criteria:

- Cancer
- Spinal infection
- Spondylopathy
- Recent Trauma
- Major organ transplant
- Fragility Fractures
- Intravenous drug abuse
- Prolonged use of corticosteroids
- Palliative Care
- Neurologic impairment
- Osteoporosis
- Hospice/Hospice services anytime during 2023
- HIV
- Lumbar surgery
- Members who died any time during 2023

# Use of Imaging Studies for Low Back Pain (LBP)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to Uncomplicated Low Back Pain Value Set

### CPT codes

Imaging Study	72020, 72052, 72100, 72110, 72114, 72120, 72131-72133, 72141, 72142, 72146-72149, 72156, 72158, 72200, 72202, 72220
Observation	99217-99220
Osteopathic and Chiropractic Manipulative Treatment	98925-98929, 98940-98942
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Outpatient G0402, G0438, G0439, G0463, T1015

### Exclusion(s)

History of Malignant Neoplasm, HIV, Hospice Care, Intravenous Drug Abuse, Major Organ Transplant, Malignant Neoplasms, Neurologic Impairment, Other Malignant Neoplasm of Skin, Other Neoplasms, Prolonged Use of Corticosteroids, Recent Trauma, Spinal Infection, Palliative Care.

# Lead Screening in Children (LSC)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: Which members are included in the sample?

**A:** Children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation in the medical record must include both of the following:

- A note indicating the date the test was performed.
- The result or finding.

## Q: What type of document is acceptable?

**A:** Evidence of claims/encounter/medical record of at least one lead capillary or venous blood test on or before the child's second birthday and the result or finding.

## Q: How to improve score for this HEDIS® measure?

**A:** Documentation in the medical record must include both of the following:

- Use of complete and accurate Value set Codes
- Timeline submission of claim/encounter data
- Exclusion:
  - Members in hospice or using hospice services in 2023
  - Members who died any time in 2023

# Lead Screening in Children (LSC)

State Medicaid MPL (must achieve 50th percentile or greater)

---

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Code

83655

### Exclusion(s)

Hospice care

# Oral Evaluation, Dental Services (OED)

## Q: Which members are included in the sample?

**A:** Members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set codes
- Timely submission of claim/encounter data.

## Exclusion(s)

- Members in hospice or using hospice services in 2023
- Members who died any time in 2023

# Oral Evaluation, Dental Services (OED)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Code

Oral Evaluation D0120, d0145, d0150

### Exclusion(s)

Hospice care

# Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Women 67-85 years of age who suffered a fracture (07/01/2022-06/30/2023), and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence of claim/encounter data:

- Bone Mineral Density (BMD) test, in any setting, on the Index Episode Start Date (IESD) or in the 180-day (6 month) period after the IESD
- If IESD was an inpatient, a BMD test during inpatient stay
- Osteoporosis therapy on the IESD or in the 180-day (6 month) period after IESD
- If the IESD was an inpatient, long-acting osteoporosis therapy during the inpatient stay
- A dispensed prescription to treat osteoporosis on the IESD or in the 180-day (6 month) period after IESD
- A dispensed prescription to treat osteoporosis
- Fracture
- Visit type

### Osteoporosis Medications

Description	Prescription
Biphosphonates	<ul style="list-style-type: none"><li>• Alendronate</li><li>• Alendronate-cholecalciferol</li><li>• Ibandronate</li><li>• Risedronate</li><li>• Zoledronic Acid</li></ul>
Other agents	<ul style="list-style-type: none"><li>• Abaloparatide</li><li>• Romosozumab</li><li>• Denosumab</li><li>• Raloxifene</li><li>• Teriparatide</li></ul>

# Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation
- ☑ **Exclusions:**
  - Members who had a BMD test during the 730 days (24 months) prior to IESD\*
  - Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to IESD\*
  - Member who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days (12 months) prior to IESD\*
  - Members who received palliative care during the intake period through the end of 2023.
  - Members in hospice or using hospice services anytime during 2023.
  - Members who are enrolled in an Institutional SNP (I-SNP) any time in 2023.
  - Members living long-term in an institution any time in 2023.
  - Members who died any time during 2023.

**Note: *Fractures of finger, toe, face and skull are not included.***

\*IESD: Index Episode Start Date [The earliest date of service for any encounter during the Intake Period (07/01/2022-06/30/2023) with a diagnosis of fracture]



# Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to Fractures Value Set

### CPT codes

Bone Mineral Density Tests	76977, 77078, 77080, 77081, 77082, 77085, 77086
Fractures	Refer to Fractures Value Set
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

Fractures	S2360
Long-Acting Osteoporosis Medications	J0897, J1740, J3489

# Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

HCPCS codes	
Osteoporosis Medications	J0630, J0897, J1740, J3110, J3489,
Outpatient	G0402, G0438, G0439, G0463, T1015

Exclusion(s)
Advanced Illness, Bone Mineral Density Tests, Frailty, Hospice, Osteoporosis Medications, Palliative Care Assessment Value Set, Palliative Care Encounter Value Set, Palliative Care Intervention Value Set.

# Osteoporosis Screening in Older Women (OSW)

## Q: Which members are included in the sample?

**A:** Women 65–75 years of age who received osteoporosis screening in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from a claim/encounter with a date of service for one or more osteoporosis screening tests on or between the member's 65th birthday and December 31, 2023.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes.
- Timely submission of claims and encounter data
- Use of accurate Exclusion Codes

### **Exclusions:**

- Members who had a claim/encounter for osteoporosis therapy any time in the member's history through December 31, 2023.
- Members who had a dispensed prescription to treat osteoporosis anytime on or between January 1, 2020 through December 31, 2023.
- Members receiving palliative care in 2023.
- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023.

### **Dementia Medication List**

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"><li>• Donepezil</li><li>• Galantamine</li><li>• Rivastigmine</li></ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"><li>• Memantine</li></ul>
Dementia combinations	<ul style="list-style-type: none"><li>• Donepezil-memantine</li></ul>

# Osteoporosis Screening in Older Women (OSW)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

N/A

### CPT codes

76977, 77078, 77080, 77081, 77085

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

N/A

### Exclusion(s)

Terminal cancer, end-of-life care planning, Palliative care, Treatment due to osteoporosis or bone loss. Hospice setting, Comprehensive management and care coordination for advanced illness, Direct skilled nursing services of a registered nurse.

# Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Members 18 years of age and older who were hospitalized and discharged from July 1, 2022 to June 30, 2023 with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data of an acute inpatient discharge with any diagnosis of AMI from July 1, 2022 to June 30, 2023 and at least 135 days of treatment with beta-blockers during the 180-day measurement interval.

### Beta-Blocker Medications

Description	Prescription
Noncardioselective beta-blockers	<ul style="list-style-type: none"> <li>Carvedilol</li> <li>Labetalol</li> <li>Nadolol</li> <li>Pindolol</li> <li>Propranolol</li> <li>Timolol</li> <li>Sotalol</li> </ul>
Cardioselective beta-blockers	<ul style="list-style-type: none"> <li>Acebutolol</li> <li>Atenolol</li> <li>Betaxolol</li> <li>Bisoprolol</li> <li>Metoprolol</li> <li>Nebivolol</li> </ul>
Antihypertensive Combinations	<ul style="list-style-type: none"> <li>Atenolol-chlorthalidone</li> <li>Bendroflumethiazide-nadolol</li> <li>Bisoprolol-hydrochlorothiazide</li> <li>Hydrochlorothiazide-metoprolol</li> <li>Hydrochlorothiazide-propranolol</li> </ul>

## Q: How to improve score for this HEDIS® measure?

**A:** Use of complete and accurate Value Set Codes. Timely submission of claim/encounter data. Exclude members identified as having intolerance or allergy to beta blocker therapy. Any of the following meet criteria:

- Asthma
- COPD
- Obstructive chronic bronchitis
- Chronic respiratory conditions due to fumes and vapors
- Hypotension, heart block >1 degree or sinus bradycardia
- A medication dispensing event indicative of a history or asthma
- Intolerance or allergy to beta-blocker therapy

### Exclusions:

- Members in hospice or using hospice services anytime during 2023
- Members enrolled in an Institutional SNP (I-SNP) any time on or between July 1, 2022 to December 31, 2023.
- Members living long-term in an institution any time on or between July 1
- Members with a dispensed dementia medication in 2023
- Members 81 years of age and older with frailty diagnosis any time on or between July 1 2022 to December 31, 2023.
- Members who died any time during 2023

# Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

AMI

I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4

### UBREV codes

Refer to Inpatient Stay Value Set

### Exclusion(s)

Advanced Illness, Adverse Effects of Beta-Adrenoreceptor Antagonists, Asthma, Beta-Blockers Contraindications, Chronic Respiratory Conditions Due to Fumes/Vapors, COPD, Frailty, Obstructive Chronic Bronchitis

# Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** Members 40 years of age and older with COPD exacerbations who had an acute inpatient discharge or ED visit on or between January 1, 2023 – November 30, 2023, and who were dispensed a systemic corticosteroid within 14 days of the event and/or a bronchodilator within 30 days of the event.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data

1. Dispensed prescription for systemic corticosteroid on or 14 days after the Episode Date.

### Systemic Corticosteroid Medications

Description	Prescription
Glucocorticoids	<ul style="list-style-type: none"><li>• Cortisone-acetate</li><li>• Hydrocortisone</li><li>• Prednisolone</li><li>• Dexamethsone</li><li>• Methylprednisolone</li><li>• Prednisone</li></ul>

# Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: What type of document is acceptable?

A:

2. Dispensed prescription for a bronchodilator on or 30 days after the Episode Date.

### Bronchodilator Medications

Description	Prescription
Anticholinergic agents	<ul style="list-style-type: none"><li>• Acclidinium-Bromide</li><li>• Tiotropium</li><li>• Ipratropium</li><li>• Umeclidinium</li></ul>
Beta 2-agonists	<ul style="list-style-type: none"><li>• Albuterol</li><li>• Arformoterol</li><li>• Formoterol</li><li>• Indacaterol</li><li>• Levalbuterol</li><li>• Metaproterenol</li><li>• Salmeterol</li><li>• Olodaterol</li></ul>
Bronchodilator combinations	<ul style="list-style-type: none"><li>• Albuterol-ipratropium</li><li>• Budesonide-formoterol</li><li>• Fluticasone-vilanterol</li><li>• Fluticasone furoate-umeclidinium-vilanterol</li><li>• Fluticasone-salmeterol</li><li>• Formoterol-acclidinium</li><li>• Formoterol-glycopyrrolate</li><li>• Formoterol-mometasone</li><li>• Olodaterol-tiotropium</li><li>• Umeclidinium-vilanterol</li></ul>

## Q: How to improve score for this HEDIS® measure?

A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023.



# Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Chronic Bronchitis	J41.0, J41.1, J41.8, J42
Emphysema	J43.0, J43.1, J43.2, J43.8, J43.9
COPD	J44.0, J44.1, J44.9

### CPT codes

ED	99281-99285
----	-------------

### HCPCS codes

N/A

### Exclusion(s)

Inpatient Stay, Nonacute Inpatient Stay

# Plan All-Cause Readmissions (PCR) Star Measure

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the sample?

**A:** For members 18 years of age and older, the number of acute inpatient and observation stays in 2023 that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.

- Count of Index Hospital Stays (IHS) (denominator)
- Count of Observed 30-Day Readmissions (numerator)
- Count of Expected 30-Day Readmissions

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data of at least one acute readmission for any diagnosis within 30 days of the Index Discharge Date (on or between January 1 and December 1, 2023).

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Review discharges and verify that they are for acute IP stays. Some maybe sub-acute, transitional care, rehab, etc.
- Schedule a follow-up once member has been discharged from the hospital to assess how the member doing to avoid possible readmission
- Capture all diagnoses as this is a case mix adjusted rate. *The sicker the member, the higher probability of a readmission*

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023

# Postpartum Depression Screening and Follow-Up (PDS-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: Which members are included in the sample?

**A:**

- ☑ Members who delivered that were screened for clinical depression during the postpartum period, and if screened positive, received follow-up care.
  - *Depression Screening.* Members who delivered that were screened for clinical depression using a standardized instrument during the postpartum period.
  - *Follow-Up on Positive Screen.* Members that delivered who received follow-up care within 30 days of a positive depression screen finding.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

# Postpartum Depression Screening and Follow-Up (PDS-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: What type of document is acceptable?

- A:**
- Evidence from claim/encounter data including pharmacy data
  - A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Instruments for Adolescents (≤17 years)	Positive Finding
Patient Health Questionnaire (PHQ-9) <sup>®</sup>	Total score ≥10
Patient Health Questionnaire Modified for Teens (PHQ-9M) <sup>®</sup>	Total score ≥10
Patient Health Questionnaire-2 (PHQ-2) <sup>®1</sup>	Total score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS) <sup>®1,2</sup>	Total score ≥8
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total score ≥17
Edinburgh Postnatal Depression Scale (EPDS)	Total score ≥10
PROMIS Depression	Total score (T Score) ≥60

Instruments for Adults (18+ years)	
My Mood Monitor (M-3) <sup>®</sup>	Total score ≥5
PROMIS Depression	Total score (T Score) ≥60
Clinically Useful Depression Outcome Scale (CUDOS)	Total score ≥31

# Postpartum Depression Screening and Follow-Up (PDS-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data.
- ☑ Documented result for depression screening, using an age-appropriate standardized instrument, performed during the 7–84 days following the date of delivery.

#### ☑ **Depression Screening**

- Depression screening captured in health risk assessments or other types of health assessments are allowed if the questions align with a specific instrument that is validated for depression screening. *For example, if a health risk assessment includes questions from the PHQ-2, it counts as screening if the member answered the questions and a total score is calculated*

#### ☑ **Follow-Up on Positive Screen**

- Documentation of members received follow-up care on or up to 30 days after the date of the first positive screen (31 total days).

Any of the following on or up to 30 days after the first positive screen

- An outpatient, telephone, e-visit or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition.
- A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.
- A behavioral health encounter, including assessment, therapy, collaborative care or medication management.
- A dispensed antidepressant medication

#### **OR**

- Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument.

## Exclusion(s)

Deliveries in which members were in hospice or using hospice services any time during the measurement period.

# Postpartum Depression Screening and Follow-Up (PDS-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT codes

Outpatient

90791-90792, 90832-90834, 90836-90847, 90849-90865, 90867-90870, 90875-90887, 98960-98962, 98966-98972, 99078, 99201-99205, 99211-99215

### HCPCS codes

Outpatient

G0071, G0463, G2010, G2012, G2061-G2063, T1015

# Prenatal Depression Screening and Follow-Up (PND-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: Which members are included in the sample?

**A:** Members who delivered that were screened for clinical depression while pregnant and, if screened positive, received follow-up care.

- *Depression Screening.* Members who delivered and were screened for clinical depression during pregnancy using a standardized instrument.
- *Follow-Up on Positive Screen.* Members who delivered and received follow-up care within 30 days of a positive depression screen finding.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

- A:**
- Evidence from claim/encounter data including pharmacy data
  - A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Instruments for Adolescents (≤17 years)	Positive Finding
Patient Health Questionnaire (PHQ-9) <sup>®</sup>	Total score ≥10
Patient Health Questionnaire Modified for Teens (PHQ-9M) <sup>®</sup>	Total score ≥10
Patient Health Questionnaire-2 (PHQ-2) <sup>®1</sup>	Total score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS) <sup>®1,2</sup>	Total score ≥8
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total score ≥17
Edinburgh Postnatal Depression Scale (EPDS)	Total score ≥10
PROMIS Depression	Total score (T Score) ≥60

Instruments for Adults (18+ years)	
My Mood Monitor (M-3) <sup>®</sup>	Total score ≥5
PROMIS Depression	Total score (T Score) ≥60
Clinically Useful Depression Outcome Scale (CUDOS)	Total score ≥31

# Prenatal Depression Screening and Follow-Up (PND-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data.
- ☑ Documented result for depression screening, using an age-appropriate standardized instrument, performed during the 7–84 days following the date of delivery.

#### ☑ **Depression Screening**

- Depression screening captured in health risk assessments or other types of health assessments are allowed if the questions align with a specific instrument that is validated for depression screening. *For example, if a health risk assessment includes questions from the PHQ-2, it counts as screening if the member answered the questions and a total score is calculated*

#### ☑ **Follow-Up on Positive Screen**

- Documentation of members received follow-up care on or up to 30 days after the date of the first positive screen (31 total days).

Any of the following on or up to 30 days after the first positive screen

- An outpatient, telephone, e-visit or virtual check-in follow-up visit with a diagnosis of depression or other behavioral health condition.
- A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.
- A behavioral health encounter, including assessment, therapy, collaborative care or medication management.
- A dispensed antidepressant medication

#### **OR**

- Documentation of additional depression screening on a full-length instrument indicating either no depression or no symptoms that require follow-up (i.e., a negative screen) on the same day as a positive screen on a brief screening instrument.

## Exclusion(s)

- Deliveries that occurred at less than 37 weeks gestation
- Deliveries in which members were in hospice or using hospice services any time during the measurement period.



# Prenatal Depression Screening and Follow-Up (PND-E)

State Medicaid MPL (must achieve 50th percentile or greater)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT codes

Outpatient	98960-98962, 98966-98972, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99366, 99492, 99493, 99494, 90791-90792, 90832-90834, 90836-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875-90876, 90880, 90887, 99484, 99492-99493
------------	--

### HCPCS codes

Outpatient	G0155, G0176-G0177, G0409-G0411, G0511-G0512, H0002, H0004, H0031, H0034-H0037, H0039-H0040, H2000-H2001, H2010-H2020, G0512, T1016-T1017, T2022-T2023, G2061-G2063
------------	---

# Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:**

- Members who delivered (EDD) between October 8, 2022 to October 7, 2023, *and*
- Had a prenatal care visits in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization, *and*
- Had a postpartum visit on or between 7 and 84 days after delivery

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is acceptable?

### Prenatal Care Visit (First Trimester, on date of enrollment, or within 42 days of enrollment)

- I. Documentation indicating the member is pregnant or references to the pregnancy; for example:
  - a. Documentation in a standardized prenatal flow sheet, or
  - b. Documentation of LMP, EDD or gestational age, or – A positive pregnancy test result, or
  - c. Documentation of gravidity and parity, or
  - d. Documentation of complete obstetrical history, or
  - e. Documentation of prenatal risk assessment and counseling/education.
- ii. A basic physical obstetrical examination that includes auscultation for fetal heart tone, or pelvic exam with obstetric observations, or measurement of fundus height (a standardized prenatal flow sheet may be used).
- iii. Evidence that a prenatal care procedure was performed, such as:
  - a. Screening test in the form of an obstetric panel (must include all of the following: hematocrit, differential WBC count, platelet count, hepatitis B surface antigen, rubella antibody, syphilis test, RBC antibody screen, Rh and ABO blood typing), or
  - b. TORCH antibody panel alone, or
  - c. A rubella antibody test/titer with an Rh incompatibility (ABO/Rh) blood typing, or
  - d. Ultrasound of a pregnant uterus.

### Post-partum Visit (7 and 84 days after delivery)

Progress note with documentation of:

- i. Pelvic exam
- ii. Evaluation of weight, BP, breasts and abdomen.
  - Notation of “breastfeeding” is acceptable for the “evaluation of breasts” component.
- iii. Notation of postpartum care, including, but not limited to: – Notation of “postpartum care,” “PP care,” “PP check,” “6-week check.”
  - A preprinted “Postpartum Care” form in which information was documented during the visit.
- iv. Perineal or cesarean incision/wound check.
- v. Screening for depression, anxiety, tobacco use, substance use disorder, or preexisting mental health disorders.
- vi. Glucose screening for women with gestational diabetes.
- vii. Documentation of any of the following topics:
  - a. Infant care or breastfeeding.
  - b. Resumption of intercourse, birth spacing or family planning.
  - c. Sleep/fatigue.
  - d. Resumption of physical activity.
  - e. Attainment of healthy weight.

# Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claims/encounter data
- ☑ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for both Timeliness of Prenatal Care and Postpartum Care
- ☑ Ensure presence of all components in the medical record documentation
- ☑ May use EDD to identify the first trimester for Timeliness of Prenatal Care and use the date of delivery for the Postpartum rate
- ☑ Documentation of deliveries **NOT** resulting in a Live Birth – *proper coding or documentation will assist in excluding members from the HEDIS® sample*

### **Exclusion:**

- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023.

# Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 Pregnancy codes

Refer to Pregnancy Diagnosis Value Set

### CPT Delivery codes

59400, 59409, 59410, 59510, 59514, 59515, 59610, 59612, 59614, 59618, 59620, 59622

## PRENATAL CARE

### CPT Prenatal Ultrasound codes

76801, 76805, 76811, 76813, 76815-76821, 76825-76828

# Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Stand Alone Prenatal Visit code

99500

### CPT Prenatal Visit codes

99201-99205, 99211-99215, 99241-99245, 99483

### CPT II Stand Alone Prenatal Visit codes

0500E, 0501E, 0502F

### CPT Prenatal Bundled Service codes

59400, 59425, 59426, 59510, 59610, 59618

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS Prenatal codes

Prenatal Visits

G0463, T1015

Stand Alone Prenatal Visits

H1000-H1004

Prenatal Bundled Services

H1005

## POSTPARTUM CARE

### ICD-10 Postpartum Visit codes

Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2

# Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Postpartum Visit codes

57170, 58300, 59430, 99501

### CPT II Postpartum Visit codes

0503F

### CPT Postpartum Bundled Service codes

59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622

### HCPCS Postpartum codes

Postpartum Visits

G0101

Cervical Cytology

G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091

### Exclusion(s)

Non-Live Births

# Prenatal Immunization Status (PRS-E)

## Q: Which members are included in the sample?

**A:** Members who delivered in the measurement period and had received influenza and tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccinations.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

- A:**
- Evidence from claim/encounter data.

## Q: How to improve score for this HEDIS® measure?

- A:**
- ☑ Use of complete and accurate Value Set Codes
  - ☑ Timely submission of claims/encounter data
  - ☑ **Immunization Status: Influenza**
    - Documentation where members received an adult influenza vaccine on or between July 1 2022 to 2023 and the delivery date, **or**
    - Documentation where members had anaphylaxis due to the influenza vaccine on or before the delivery date.
  - ☑ **Immunization Status: Tdap**
    - Documentation where members received at least one Tdap vaccine during the pregnancy (including on the delivery date), **or**
    - Documentation where members had any of the following:
      - Anaphylaxis due to the diphtheria, tetanus or pertussis vaccine on or before the delivery date.
      - Encephalitis due to the diphtheria, tetanus or pertussis vaccine on or before the delivery date.

# Prenatal Immunization Status (PRS-E)

## Exclusion(s)

- Deliveries that occurred at less than 37 weeks gestation.
- Deliveries in which members were in hospice or using hospice services any time during the measurement period.

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

## CPT Codes

Outpatient	90630, 90653-90654, 90656, 90658, 90661-90662, 90673-90674, 90682, 90686, 90688-90689, 90694, 90715, 90756
------------	--



# Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the SAMPLE?

**A:** Males 21 – 75 years of age and members 40 – 75 years of age who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high or moderate-intensity statin medication in 2023 and remained on it for at least 80% of the treatment period.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

1. *Received Statin Therapy.* Dispensed prescription for a high or moderate-intensity statin medication in 2023

### High- and Moderate-Intensity Statin Medications:

Description	Prescription	Medication Lists
High-intensity statin therapy	• Atorvastatin 40-80 mg	• Atorvastatin High Intensity Medications List
	• Amlodipine-atorvastatin 40-80 mg	• Amlodipine Atorvastatin High Intensity Medications List
	• Rosuvastatin 20-40 mg	• Rosuvastatin High Intensity Medications List
	• Simvastatin 80 mg	• Simvastatin High Intensity Medications List
	• Ezetimibe-simvastatin 80 mg	• Ezetimibe Simvastatin High Intensity Medications List

# Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Description	Prescription	Medication Lists
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg	• Atorvastatin Moderate Intensity Medications List
	• Amlodipine-atorvastatin 10-20 mg	• Amlodipine Atorvastatin Moderate Intensity Medications List
	• Rosuvastatin 5-10 mg	• Rosuvastatin Moderate Intensity Medications List
	• Simvastatin 20-40 mg	• Simvastatin Moderate Intensity Medications List
	• Ezetimibe-simvastatin 20-40 mg	• Ezetimibe Simvastatin Moderate Intensity Medications List
	• Pravastatin 40-80 mg	• Pravastatin Moderate Intensity Medications List
	• Lovastatin 40 mg	• Lovastatin Moderate Intensity Medications List
	• Fluvastatin 40-80 mg	• Fluvastatin Moderate Intensity Medications List
	• Pitavastatin 2–4 mg	• Pitavastatin Moderate Intensity Medications List

## EXCLUSIONS:

### Estrogen Agonist Medications:

Description	Prescription
Estrogen agonists	• Clomiphene

### Dementia Medications

Description	Prescription
Cholinesterase inhibitors	• Donepezil • Galantamine • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine

# Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: What type of documentation is acceptable?

2. *Statin Adherence 80%*. Proportion of days covered (PDC) by prescription medication for at least 80% of the treatment period based on pharmacy claims from earliest dispensing event in 2023.

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Services provided during a telephone visit, e-visit or virtual check-in meet criteria for advanced illness exclusion.

## Exclusion(s)

- Members with a diagnosis of pregnancy during 2022-2023.
- In vitro fertilization during 2022-2023.
- Dispensed at least one prescription for clomiphene during 2022-2023.
- ESRD diagnosis during 2022-2023.
- Cirrhosis diagnosis during 2022-2023.
- Myalgia, myositis, myopathy or rhabdomyolysis during 2023.
- Members in hospice or using hospice services anytime during 2023.
- Members receiving palliative care during 2023.
- Members who died any time during 2023.

# Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to IVD Value Set and MI Value Set; Old Myocardial Infarction Value Set

### CPT codes

Acute Inpatient	99221 – 99223, 99231 – 99233, 99238, 99239, 99251-99255, 99291
CABG	33510 – 33514, 33516 – 33519, 33521 – 33523, 33533 – 33536
Other Revascularization	37220, 37221, 37224 – 37231
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
PCI	92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### HCPCS codes

CABG	S2205 – S2209
PCI	C9600, C9602, C9604, C9606, C9607

### Exclusion(s)

Advanced Illness, Cirrhosis, ESRD, Frailty, IVE, Muscular Pain and Disease, Pregnancy, Encounter for Palliative Care

# Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: Which members are included in the SAMPLE?

**A:** Members 40 – 75 years of age with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one statin medication of any intensity in 2023 and remained on it for at least 80% of the treatment period.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data

1. *Received Statin Therapy.* Dispensed prescription for a high, moderate, or low-intensity statin medication in 2023

### High- and Moderate-Intensity Statin Medications:

Description	Prescription	Medication Lists
High-intensity statin therapy	• Atorvastatin 40-80 mg	• Atorvastatin High Intensity Medications List
	• Amlodipine-atorvastatin 40-80 mg	• Amlodipine Atorvastatin High Intensity Medications List
	• Rosuvastatin 20-40 mg	• Rosuvastatin High Intensity Medications List
	• Simvastatin 80 mg	• Simvastatin High Intensity Medications List
	• Ezetimibe-simvastatin 80 mg	• Ezetimibe Simvastatin High Intensity Medications List

# Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Description	Prescription	Medication Lists
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg	• Atorvastatin Moderate Intensity Medications List
	• Amlodipine-atorvastatin 10-20 mg	• Amlodipine Atorvastatin Moderate Intensity Medications List
	• Rosuvastatin 5-10 mg	• Rosuvastatin Moderate Intensity Medications List
	• Simvastatin 20-40 mg	• Simvastatin Moderate Intensity Medications List
	• Ezetimibe-simvastatin 20-40 mg	• Ezetimibe Simvastatin Moderate Intensity Medications List
	• Pravastatin 40-80 mg	• Pravastatin Moderate Intensity Medications List
	• Lovastatin 40 mg	• Lovastatin Moderate Intensity Medications List
	• Fluvastatin 40-80 mg	• Fluvastatin Moderate Intensity Medications List
	• Pitavastatin 1–4 mg	• Pitavastatin Moderate Intensity Medications List
Low-intensity statin therapy	• Ezetimibe-simvastatin 10 mg	• Ezetimibe Simvastatin Low Intensity Medications List
	• Fluvastatin 20 mg	• Fluvastatin Low Intensity Medications List
	• Lovastatin 10-20 mg	• Lovastatin Low Intensity Medications List
	• Pitavastatin 1 mg	• Pitavastatin Low Intensity Medications List
	• Pravastatin 10–20 mg	• Pravastatin Low Intensity Medications List
	• Simvastatin 5-10 mg	• Simvastatin Low Intensity Medications List

# Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## Q: What type of document is acceptable?

### EXCLUSIONS:

#### Estrogen Agonist Medications:

Description	Prescription
Estrogen agonists	<ul style="list-style-type: none"><li>• Clomiphene</li></ul>

#### Dementia Medications

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"><li>• Donepezil</li><li>• Galantamine</li><li>• Rivastigmine</li></ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"><li>• Memantine</li></ul>
Dementia combinations	<ul style="list-style-type: none"><li>• Donepezil-memantine</li></ul>

2. *Statin Adherence 80%*. Proportion of days covered (PDC) by prescription medication for at least 80% of the treatment period based on pharmacy claims from earliest dispensing event in 2023.

## Q: How to improve score for this HEDIS® measure?

### A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Services provided during a telephone visit, e-visit or virtual check-in meet criteria for advanced illness exclusion.

## Exclusion(s)

- Members with a diagnosis of pregnancy during 2022-2023.
- In vitro fertilization during 2022-2023.
- Dispensed at least one prescription for clomiphene during 2022-2023.
- ESRD diagnosis during 2022-2023.
- Cirrhosis diagnosis during 2022-2023.
- Myalgia, myositis, myopathy or rhabdomyolysis during 2023.
- Members in hospice or using hospice services anytime during 2023.
- Members receiving palliative care during 2023.
- Members who did not have a diagnosis of diabetes and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes in 2022 or 2023.
- Members who died any time during 2023

# Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Refer to Diabetes Value Set

### CPT codes

Acute Inpatient	99221 – 99223, 99231 – 99233, 99238, 99239, 99251 – 99255, 99291
Outpatient	99201 – 99205, 99211 – 99215, 99241 – 99245, 99341 – 99345, 99347 – 99350, 99381 – 99387, 99391 – 99397, 99401 – 99404, 99411, 99412, 99429, 99455, 99456, 99483
Nonacute Inpatient	99304 – 99310, 99315, 99316, 99318, 99324 – 99328, 99334 – 99337

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

### CPT Modifier codes for telehealth

95, GT, 02

### Exclusion(s)

Advanced Illness, CABG, Cirrhosis, Diabetes, Diabetes Exclusions, ESRD, Frailty, IVD, IVE, MI Value Set; Old Myocardial Infarction Value, Muscular Pain and Disease, Other Revascularization, PCI, Pregnancy



# Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

## Q: Which members are included in the SAMPLE?

**A:** Members 40 years of age and older with a new diagnosis of COPD or newly active COPD, who received appropriate spirometry testing to confirm the diagnosis.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data:

- At least one spirometry test confirming diagnosis of Chronic Obstructive Pulmonary Disease (COPD) during the 730 days (2 years) prior to the IESD through 180 days (6 months) after the IESD.

**Index Episode Start Date (IESD):** The earliest date of service for an eligible visit (outpatient, ED, or acute inpatient) during the Intake Period (July 1, 2022 - June 30, 2023) with any diagnosis of COPD.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Services provided during a telephone visit, e-visit or virtual check-in meet criteria for eligible population.

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023.

# Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

## SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
Chronic Bronchitis	J41.0, J41.1, J41.8, J42
Emphysema	J43.0, J43.1, J43.2, J43.8, J43.9
COPD	J44.0, J44.1, J44.9
CPT codes	
Spirometry	94010, 94014-94016, 94060, 94070, 94375, 94620
ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015
Exclusion(s)	
Chronic Bronchitis, COPD, Emphysema, Inpatient Stay, Nonacute Inpatient Stay, Telehealth Modifier, Telehealth POS	

# Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Adults 18- 64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a glucose test or an HbA1c test in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes and pharmacy data.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter or lab data:

- Glucose test in 2023
- HbA1c test in 2023

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Services provided during a telephone visit, e-visit or virtual check-in meet criteria for eligible population.

## Exclusions

**A:**

- Members with diabetes identified by claim/encounter and pharmacy data in 2022 or 2023
- Members who were dispensed insulin or oral hypoglycemics/antihyperglycemics in 2022 or 2023
- Members who had no antipsychotic medications dispensed in 2023
- Members in hospice or using hospice services anytime during 2023.
- Members who died any time during 2023.

# Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

## Antipsychotic Medications

### Diabetes Medications

Description	Prescription
Alpha-glucosidase inhibitors	<ul style="list-style-type: none"> <li>Acarbose</li> <li>Miglitol</li> </ul>
Amylin analogs	<ul style="list-style-type: none"> <li>Pramlintide</li> </ul>
Antidiabetic combinations	<ul style="list-style-type: none"> <li>Alogliptin-metformin</li> <li>Alogliptin-pioglitazone</li> <li>Canagliflozin-metformin</li> <li>Dapagliflozin-metformin</li> <li>Dapagliflozin-saxagliptin</li> <li>Empagliflozin-linagliptin</li> <li>Empagliflozin-linagliptin-metformin</li> <li>Empagliflozin-metformin</li> <li>Ertugliflozin-metformin</li> <li>Ertugliflozin-sitagliptin</li> <li>Glimepiride-pioglitazone</li> <li>Glipizide-metformin</li> <li>Glyburide-metformin</li> <li>Linagliptin-metformin</li> <li>Metformin-pioglitazone</li> <li>Metformin-repaglinide</li> <li>Metformin-rosiglitazone</li> <li>Metformin-saxagliptin</li> <li>Metformin-sitagliptin</li> </ul>
Insulin	<ul style="list-style-type: none"> <li>Insulin aspart</li> <li>Insulin aspart-insulin aspart protamine</li> <li>Insulin degludec</li> <li>Insulin degludec-liraglutide</li> <li>Insulin detemir</li> <li>Insulin glargine-lixisenatide</li> <li>Insulin glargine</li> <li>Insulin glulisine</li> <li>Insulin isophane human</li> <li>Insulin isophane-insulin regular</li> <li>Insulin lispro</li> <li>Insulin lispro-insulin lispro protamine</li> <li>Insulin regular human</li> <li>Insulin human inhaled</li> </ul>
Meglitinides	<ul style="list-style-type: none"> <li>Nateglinide</li> <li>Repaglinide</li> </ul>
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> <li>Dulaglutide</li> <li>Liraglutide (excluding Saxenda®)</li> <li>Semaglutide</li> <li>Albiglutide</li> <li>Exenatide</li> </ul>
Sodium glucose cotransporter 2 (SGLT2) inhibitor	<ul style="list-style-type: none"> <li>Canagliflozin</li> <li>Empagliflozin</li> <li>Ertugliflozin</li> <li>Dapagliflozin</li> </ul>
Sulfonylureas	<ul style="list-style-type: none"> <li>Chlorpropamide</li> <li>Glimepiride</li> <li>Tolazamide</li> <li>Glipizide</li> <li>Glyburide</li> <li>Tolbutamide</li> </ul>
Thiazolidinediones	<ul style="list-style-type: none"> <li>Pioglitazone</li> <li>Rosiglitazone</li> </ul>
Dipeptidyl peptidase-4 (DDP-4) inhibitors	<ul style="list-style-type: none"> <li>Alogliptin</li> <li>Linagliptin</li> <li>Saxagliptin</li> <li>Sitagliptin</li> </ul>

# Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

## Antipsychotic Medications

### SSD Antipsychotic Medications

Description	Prescription
Miscellaneous antipsychotic agents	<ul style="list-style-type: none"> <li>Aripiprazole</li> <li>Asenapine</li> <li>Brexpiprazole</li> <li>Cariprazine</li> <li>Clozapine</li> <li>Lumateperone</li> <li>Haloperidol</li> <li>Iloperidone</li> <li>Loxapine</li> <li>Lurasidone</li> <li>Molindone</li> <li>Olanzapine</li> <li>Paliperidone</li> <li>Quetiapine</li> <li>Risperidone</li> <li>Ziprasidone</li> </ul>
Phenothiazine antipsychotics	<ul style="list-style-type: none"> <li>Chlorpromazine</li> <li>Fluphenazine</li> <li>Perphenazine</li> <li>Prochlorperazine</li> <li>Thioridazine</li> <li>Trifluoperazine</li> </ul>
Psychotherapeutic combinations	<ul style="list-style-type: none"> <li>Amitriptyline-perphenazine</li> </ul>
Thioxanthenes	<ul style="list-style-type: none"> <li>Thiothixene</li> </ul>
Long-acting injections	<ul style="list-style-type: none"> <li>Aripiprazole</li> <li>Aripiprazole lauroxil</li> <li>Fluphenazine decanoate</li> <li>Haloperidol decanoate</li> <li>Olanzapine</li> <li>Paliperidone palmitate</li> <li>Risperidone</li> </ul>

# Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes*

### ICD-10 codes

F20.9 Schizophrenia, unspecified

F31.9 Bipolar disorder, unspecified

F30.9 Manic episode, unspecified

### CPT codes

Non Acute Inpatient 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337

Acute Inpatient 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291

### HCPCS codes

Annual wellness visit; includes a personalized prevention plan of service, initial visit G0438

Behavioral health counseling and therapy, per 15 minutes H0004

Mental health assessment, by non-physician H0031

Comprehensive medication services, per 15 minutes H2010

Skills training and development, per 15 minutes H2014

Therapeutic behavioral services, per 15 minutes H2019

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### Exclusion(s)

Diabetes, Long-Acting Injections, SSD Antipsychotic Medications List

# Topical Fluoride for Children (TFC)

## Q: Which members are included in the sample?

A: Members 1-4 years of age who received at least 2 fluoride varnish applications in 2023.

## Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: What type of document is acceptable?

A: Evidence from claim/encounter or lab data:

## Q: How to improve score for this HEDIS® measure?

- A:
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data

## Exclusions:

- Members in hospice or using hospice services in 2023
- Members who died any time in 2023

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### CPT Codes

Application of topical fluoride	99188
---------------------------------	-------

### CDT Codes

Application of topical fluoride	D1206
---------------------------------	-------

### Exclusion(s)

Hospice encounter

# Transitions of Care (TRC)

## Q: Which members are included in the sample?

**A:** Member 18 years and older who were discharged from acute or in acute setting from January 1, 2023 and December 1, 2023:

- Notification of Inpatient Admission
- Receipt of Discharge Information
- Patient Engagement After Inpatient Discharge
- Medication Reconciliation Post-Discharge

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation in the medical record must include evidence of the following:

- Documentation of receipt of notification of inpatient admission on the day of admission through 2 days after the admission (3 total days).
- Documentation of receipt of discharge information on the day of discharge through 2 days after the admission (3 total days).
- Documentation of patient engagement (e.g., office visits, visits to the home, telehealth) provided within 30 days after discharge.
- Documentation of medication reconciliation on the date of discharge through 30 days after discharge (31 total days).

## Q: What type of document is acceptable?

**A:** All of the following documentation in 2023:

- Notification of Inpatient Admission
- Receipt of Discharge Information
- Patient Engagement After Inpatient Discharge
- Medication Reconciliation with medication list
- All progress notes
- Current medication list
- All correspondence (phone call, email, fax) between inpatient provider and member's PCP
- All Hospital/SNF/Rehab discharge summaries

**Medication Reconciliation does not require the member to be present**



# Transitions of Care (TRC)

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Services provided during a telephone visit, e-visit or virtual check-in within 30 days after discharge meet criteria.
- ☑ Ensure presence of all components in the medical record documentation
- ☑ Evidence that the member was seen for post discharge; hospital follow-up requires documentation that indicates the provider was aware of the member's hospitalization or discharge.

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023

# Transitions of Care (TRC)

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes*

CPT codes	
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456
Telephone Visits	98966, 98967, 98968, 99441, 99442, 99443
Transitional Care Management Services	99495, 99496
Medication Reconciliation	99483, 99495, 99496

CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	

CPT Modifier codes for telehealth	
95, GT, 02	

CPTII	
Medication Reconciliation	1111F

Modifier	
Telehealth	95, GT

# Appropriate Treatment for Children with Upper Respiratory Infection (URI)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Children 3 months and older who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription in **2022 or 2023**.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What type of document is acceptable?

**A:** Evidence from claim/encounter data with a date of service for any outpatient or ED visit with **only** a URI diagnosis and no new or refill prescription for an antibiotic on or three days after the Index Episode Start Date (IESD).  
**Index Episode Start Date (IESD):** The earliest date of service for an eligible visit (outpatient, observation, or ED) during Intake Period (July 1, 2022-June 30, 2023).

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data
  - Ensure presence of all components in the medical record documentation
  - Exclude claim/encounter data with more than one diagnosis code and ED visits or observation visits that result in an inpatient stay

## Exclusion:

- Exclude members in hospice or using hospice services anytime during 2023.
- Members who died any time during 2023.

# Appropriate Treatment for Upper Respiratory Infection (URI)

NCQA Accreditation – Medicaid

## SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

### ICD-10 codes

URI	J00, J06.0, J06.9
-----	-------------------

### CPT codes

ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
Telephone Visit	98966 -98968, 99441- 99443
Online Assessment	98969, 99444

### CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205
---

### HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

### Exclusion(s)

Competing Diagnosis, Inpatient Stay, Pharyngitis 1. HIV Value Set. 2. HIV Type 2 Value Set. 3. Malignant Neoplasms Value Set. 4. Other Malignant Neoplasm of Skin Value Set. 5. Emphysema Value Set.	6. COPD Value Set. 7. Comorbid Conditions Value Set. 8. Disorders of the Immune System Value Set. 9. Pharyngitis Value Set. 10. Competing Diagnosis Value Set.
---	--

# Well-Child Visits in the First 30 Months of Life (W30)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Children who had the following number of well-child visits with a PCP during the last 15 months.

1. Well-Child Visits in the First 15 Months. Children who turned 15 months old during the measurement year: Six or more well-child visits.
2. Well-Child Visits for Age 15 Months–30 Months. Children who turned 30 months old during the measurement year: Two or more well-child visits between 15 and 30 months of age.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** None. This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

## Q: What type of medical record is acceptable?

**A:**

1. Evidence from a claim/encounter with a date of service for any six or more well-child visits on different dates of service on or before the 15-month birthday.
2. Evidence from a claim/encounter with a date of service for any two or more well-child visits on different dates of service between the child's 15-month birthday plus 1 day and the 30-month birthday.

## Q: How to improve score for this HEDIS® measure?

**A:**

- Use of complete and accurate Value Set Codes.
- Timely submission of claims and encounter data
- Use every visit (including sick visit) to provide a well-child visit and immunizations

## Exclusion(s)

- Members in hospice or using hospice services any time during 2023.
- Members who died any time during 2023

# Well-Child Visits in the First 30 Months of Life (W30)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z02.5, Z76.1, Z76.2

### CPT codes

99381-99385, 99391-99395, 99461

### HCPCS codes

G0438, G0439, S0302

### Exclusion(s)

Hospice setting or Hospice care.

# Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of BMI percentile with height and weight documentation, counseling for nutrition, and counseling for physical activity in **2023**.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** Documentation in the medical record must include a note indicating the **date** of the office visit and evidence of the following:

- BMI percentile *or* BMI percentile plotted on age-growth chart
- Height and weight
- Counseling for nutrition or referral for nutrition education
- Counseling for physical activity or referral for physical activity

## Q: What type of medical record is acceptable?

**A:** One or more of the following:

- Progress notes/Office visits notes
- Anticipatory Guidance Form
- Staying Healthy Assessment Form
- Member-collected biometric values (height, weight, BMI percentile) meet criteria for the BMI Percentile numerator.
- Complete Physical Examination Form
- Dated growth chart/log
- Nutrition and Physical Activity Assessment Form
- What Does Your Child Eat Form

# Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

NCQA Accreditation – Medicaid

## Q: How to improve score for this HEDIS® measure?

### A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Services rendered during a telephonic visit, e-visit or virtual check-in meet criteria for the Counseling for Nutrition and Counseling for Physical Activity indicators.
- ☑ Ensure presence of all components in the medical record documentation

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023
- A diagnosis of pregnancy in 2023
- Members who died any time during 2023

*Note: Services specific to the assessment or treatment of an acute or chronic condition do not count toward the “Counseling for nutrition” and “Counseling for physical activity” indicators.*



# Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

ICD-10 codes	
BMI Percentile	Z68.51-Z68.54
Nutrition Counseling	Z71.3
Physical Activity Counseling	Z02.5, Z71.82

  

CPT codes	
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
Nutrition Counseling	97802-97804

  

CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	

  

T Modifier codes for telehealth	
95, GT, 02	

  

HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015
Nutrition Counseling	G0270, G0271, G0447, S9449, S9452, S9470
Physical Activity Counseling	G0447, S9451

  

Exclusion(s)	
Pregnancy	

# Child and Adolescent Well-Care Visits (WCV)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation – Medicaid

## Q: Which members are included in the sample?

**A:** Members 3-21 years of age who had at least one (1) comprehensive well-care visit with a PCP or an OB/GYN practitioner in 2023.

## Q: What codes are used?

**A:** Please reference attached sample codes and Value Set Directory for additional codes.

## Q: What documentation is needed in the medical record?

**A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

## Q: How to improve score for this HEDIS® measure?

- A:**
- Use every visit (including sick visits) to provide a well-child visit (Ambulatory visits, Telephone visits, Online assessments)
  - Use standardized templates for WCV in Electronic Health Records (EHR)
  - Use of complete and accurate Value Set Codes
  - Timely submission of claim/encounter data
  - Submission of telehealth claim/encounter

## Exclusion(s)

- Members in hospice or using hospice services anytime during 2023
- Members who died any time during 2023.

# Child and Adolescent Well-Care Visits (WCV)

State Medicaid MPL (must achieve 50th percentile or greater)  
Pay-for-Performance (P4P)  
NCQA Accreditation – Medicaid

## SAMPLE CODES

*The codes listed below are not inclusive and do not represent a complete list of codes.*

### ICD-10 codes

Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z02.5, Z76.1, Z76.2

### CPT codes

99381-99384, 99391-99395

### HCPCS codes

G0438, G0439, S0302

### Exclusion(s)

Hospice setting or Hospice care.